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A B S T R A C T
Background
Down’s syndrome occurs when a person has three copies of chromosome 21 (or the specific area of chromosome 21 implicated in
causing Down’s syndrome) rather than two. It is the commonest congenital cause of mental disability. Non-invasive screening based on
biochemical analysis of maternal serum or urine, or fetal ultrasound measurements, allows estimates of the risk of a pregnancy being
affected and provides information to guide decisions about definitive testing.
Before agreeing to screening tests, parents need to be fully informed about the risks, benefits and possible consequences of such a test.
This includes subsequent choices for further tests they may face, and the implications of both false positive (i.e. invasive diagnostic
testing, and the possibility that a miscarried fetus may be chromosomally normal) and false negative screening tests (i.e. a fetus with
Down’s syndrome will be missed). The decisions that may be faced by expectant parents inevitably engender a high level of anxiety
at all stages of the screening process, and the outcomes of screening can be associated with considerable physical and psychological
morbidity. No screening test can predict the severity of problems a person with Down’s syndrome will have.
Objectives
To estimate and compare the accuracy of first and second trimester serum markers with and without first trimester ultrasound markers
for the detection of Down’s syndrome in the antenatal period, as combinations of markers.
Search methods
We conducted a sensitive and comprehensive literature search of MEDLINE (1980 to 25 August 2011), Embase (1980 to 25 August
2011), BIOSIS via EDINA (1985 to 25 August 2011), CINAHL via OVID (1982 to 25 August 2011), the Database of Abstracts of
Reviews of Effectiveness (the Cochrane Library 25 August 2011), MEDION (25 August 2011), the Database of Systematic Reviews
and Meta-Analyses in Laboratory Medicine (25 August 2011), the National Research Register (Archived 2007), and Health Services
Research Projects in Progress database (25 August 2011). We did not apply a diagnostic test search filter. We did forward citation
searching in ISI citation indices, Google Scholar and PubMed ‘related articles’. We also searched reference lists of retrieved articles
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Selection criteria
Studies evaluating tests of combining first and second trimestermaternal serummarkers inwomenup to 24weeks of gestation forDown’s
syndrome, with or without first trimester ultrasound markers, compared with a reference standard, either chromosomal verification or
macroscopic postnatal inspection.
Data collection and analysis
Data were extracted as test positive/test negative results for Down’s and non-Down’s pregnancies allowing estimation of detection
rates (sensitivity) and false positive rates (1-specificity). We performed quality assessment according to QUADAS criteria. We used
hierarchical summary ROCmeta-analytical methods to analyse test performance and compare test accuracy. Analysis of studies allowing
direct comparison between tests was undertaken. We investigated the impact of maternal age on test performance in subgroup analyses.
Main results
Twenty-two studies (reported in 25publications) involving 228,615 pregnancies (including 1067withDown’s syndrome)were included.
Studies were generally high quality, although differential verification was common with invasive testing of only high risk pregnancies.
Ten studies made direct comparisons between tests. Thirty-two different test combinations were evaluated formed from combinations
of eight different tests and maternal age; first trimester nuchal translucency (NT) and the serum markers AFP, uE3, total hCG, free
βhCG, Inhibin A, PAPP-A and ADAM12.We looked at tests combining first and second trimester markers with or without ultrasound
as complete tests, and we also examined stepwise and contingent strategies.
Meta-analysis of the sixmost frequently evaluated test combinations showed that a test strategy involvingmaternal age and a combination
of first trimester NT and PAPP-A, and second trimester total hCG, uE3, AFP and Inhibin A significantly outperformed other test
combinations that involved only one serum marker or NT in the first trimester, detecting about nine out of every 10 Down’s syndrome
pregnancies at a 5% false positive rate. However, the evidence was limited in terms of the number of studies evaluating this strategy,
and we therefore cannot recommend one single screening strategy.
Authors’ conclusions
Tests involvingfirst trimester ultrasoundwith first and second trimester serummarkers in combinationwithmaternal age are significantly
better than those without ultrasound, or those evaluating first trimester ultrasound in combinationwith second trimester serummarkers,
without first trimester serum markers. We cannot make recommendations about a specific strategy on the basis of the small number of
studies available.
P L A I N L A N G U A G E S U M M A R Y
Screening tests for Down’s syndrome in the first 24 weeks of pregnancy
Background
Down’s syndrome (also known as Down’s or Trisomy 21) is an incurable genetic disorder that causes significant physical and mental
health problems, and disabilities. However, there is wide variation in how Down’s affects people. Some individuals are severely affected
whilst others have mild problems and are able to lead relatively normal lives. There is no way of predicting how badly a baby might be
affected.
Expectant parents are given the choice to be tested for Down’s syndrome during pregnancy to assist them in making decisions. If a
mother is carrying a baby with Down’s syndrome, then there is the decision about whether to terminate or continue with the pregnancy.
The information offers parents the opportunity to plan for life with a child with Down’s syndrome.
The most accurate tests for Down’s syndrome involve testing fluid from around the baby (amniocentesis) or tissue from the placenta
(chorionic villus sampling (CVS)) for the abnormal chromosomes associated with Down’s syndrome. Both these tests involve inserting
needles through the mother’s abdomen and are known to increase the risk of miscarriage. Thus, the tests may not be suitable for all
pregnant women. Rather, tests that measure markers in the mother’s blood, urine, or on ultrasound scans of the baby are used for
screening. These screening tests are not perfect as they can miss cases of Down’s syndrome and also give high risk test results to a
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number of women whose babies are not affected by Down’s syndrome. Thus, pregnancies identified as high risk using these screening
tests require further testing using amniocentesis or CVS to confirm a diagnosis of Down’s syndrome.
What we did
We assessed combinations of first trimester (up to 14 weeks’ gestation) and second trimester serum screening tests (up to 24 weeks’
gestation), with or without first trimester ultrasound screening tests, Our aim was to identify the most accurate test(s) for predicting the
risk of a pregnancy being affected by Down’s syndrome. We looked at one ultrasound marker (nuchal translucency) and seven different
serum markers (PAPP-A, total hCG, free βhCG, uE3, AFP, inhibin A, ADAM 12) that can be used alone, in ratios or in combination,
taken before 24 weeks’ gestation, thus creating 32 screening tests for Down’s. We found 22 studies, involving 228,615 pregnancies
(including 1067 fetuses affected by Down’s syndrome).
What we found
For Down’s syndrome screening, where tests were carried out in the first and second trimester and combined to give an overall risk, we
found that a test comprised of first trimester nuchal translucency and PAPP-A, and second trimester total hCG, uE3, AFP and Inhibin
A was the most sensitive test, detecting nine out of 10 pregnancies affected by Down’s syndrome. Five per cent of pregnant women
receiving a high risk test result based on this combination would not be affected by Down’s syndrome. There were relatively few studies
assessing these tests and therefore we cannot make a strong recommendation about the best test.
Other important information to consider
The ultrasound tests themselves have no adverse effects for the woman, and blood tests can cause discomfort, bruising and, rarely,
infection. However, some women who have a high risk screening test result, and are given amniocentesis or CVS have a risk of
miscarrying a baby unaffected by Down’s. Parents will need to weigh up this risk when deciding whether or not to have an amniocentesis
or CVS following a high risk screening test result.
B A C K G R O U N D
This is one of a series of reviews on antenatal screening for
Down’s syndrome following a generic protocol (Alldred 2010) -
see Published notes for more details.
Target condition being diagnosed
Down’s syndrome
Down’s syndrome affects approximately one in 800 live born ba-
bies (Cuckle 1987a). It results from a person having three, rather
than two, copies of chromosome 21 - or the specific area of chro-
mosome 21 implicated in causing Down’s syndrome - as a result of
trisomy (an additional copy of the whole chromosome) or translo-
cation (duplication of part of the chromosome caused by rear-
rangements of parts of different chromosomes, resulting in three
copies of information responsible for Down’s syndrome). If not all
cells are affected, the pattern is described as ’mosaic’. Down’s syn-
drome can cause a wide range of physical and mental problems. It
is the commonest cause of mental disability, and is also associated
with a number of congenital malformations, notably affecting the
heart. There is also an increased risk of cancers such as leukaemia,
and numerous metabolic problems including diabetes and thyroid
disease. Some of these problemsmay be life-threatening, or lead to
considerable ill health, while some individuals with Down’s syn-
drome have only mild problems and can lead a relatively normal
life.
There is no cure for Down’s syndrome, and antenatal diagnosis
allows for preparation for the birth and subsequent care of a baby
with Down’s syndrome, or for the offer of a termination of preg-
nancy. Having a baby with Down’s syndrome is likely to have a
significant impact on family and social life, relationships and par-
ents’ work. Special provisions may need to be made for education
and care of the child, as well as accommodating the possibility of
periods of hospitalisation.
Definitive invasive tests (amniocentesis and chorionic villus sam-
pling (CVS)) exist that allow the diagnosis of Down’s syndrome
before birth but carry a risk of miscarriage. No test can predict the
severity of problems a person with Down’s syndrome will have.
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Non-invasive screening tests based on biochemical analysis of ma-
ternal serum or urine, or fetal ultrasound measurements, allow
an estimate of the risk of a pregnancy being affected and provide
parents with information to enable them to make choices about
definitive testing. Such screening tests are used during the first
and second trimester of pregnancy.
Screening tests for Down’s syndrome
Initially, screening was determined solely by using maternal age to
classify a pregnancy as high or low risk for trisomy 21, as it was
known that older women had a higher chance of carrying a baby
with Down’s syndrome (Penrose 1933).
Further advances in screening were made in the early 1980s, when
Merkatz and colleagues investigated the possibility that lowmater-
nal serum alpha-fetoprotein (AFP), obtained frommaternal blood
in the second trimester of pregnancy could be associatedwith chro-
mosomal abnormalities in the fetus. Their retrospective case-con-
trol study showed a statistically significant relationship between
fetal trisomy, such as Down’s syndrome, and lowered maternal
serum AFP (Merkatz 1984). This was further explored by Cuckle
and colleagues in a larger retrospective trial using data collected
as part of a neural tube defect (NTD) screening project (Cuckle
1984a). This work was followed by calculation of risk estimates
using maternal serum AFP values and maternal age, which ulti-
mately led to the introduction of the two screening parameters in
combination (Alfirevic 2004).
In 1987, in a small case-control study of women carrying fe-
tuses with known chromosomal abnormalities, Bogart and col-
leagues investigated maternal serum levels of human chorionic go-
nadotrophin (hCG) as a possible screening tool for chromosomal
abnormalities in the second trimester (Bogart 1987). This fol-
lowed the observations that low hCG levels were associated with
miscarriages, which are commonly associated with fetal chromo-
somal abnormalities. They concluded that high hCG levels were
associated with Down’s syndrome and because hCG levels plateau
at 18 to 24 weeks, that this would be the most appropriate time
for screening. Later work suggested that the ß sub-unit of hCG
(free βhCG) was a more effective marker than total hCG (Macri
1990; Macri 1993).
Second trimester unconjugated oestriol (uE3), produced by the
fetal adrenals and the placenta, was also evaluated as a potential
screeningmarker. In another retrospective case-control study, uE3
was shown to be lower in Down’s syndrome pregnancies compared
with unaffected pregnancies. When used in combination with
AFP and maternal age, it appeared to identify more pregnancies
affected by Down’s syndrome than AFP and age alone (Canick
1988). Further work suggested that all three serum markers (AFP,
hCGanduE3) showed evenhigher detection rateswhen combined
with maternal age (Wald 1988a; Wald 1988b) and appeared to be
a cost-effective screening strategy (Wald 1992a).
Three other serum markers, produced by the placenta, have
been linked with Down’s syndrome, namely pregnancy-associated
plasma protein A or PAPP-A, inhibin A and a disintegrin and
metalloprotease 12 (ADAM12). PAPP-A has been shown to be re-
duced in the first trimester of Down’s syndrome pregnancies, with
its most marked reduction in the early first trimester (Bersinger
1995). Inhibin A is high in the second trimester in pregnancies af-
fected by Down’s syndrome (Cuckle 1995; Wallace 1995). There
are some issues concerning the biological stability - for example,
delay in samples arriving in the laboratory - and hence reliability
of this marker, and the effect this will have on individual risk.
ADAM 12 has been shown to be a potential first trimester marker
with reducedmaternal serum levels in pregnancy prior to 10 weeks
(Laigaard 2003; Spencer 2008a).
In 1992, Nicolaides and colleagues demonstrated an association
between increased nuchal translucency (NT) and chromosomal
abnormalities (Nicolaides 1992). Nuchal translucency measure-
ment requires an ultrasound scan of the fluid at the fetal neck
between 10 and 13+6 weeks’ gestation. If the amount is large, it
suggests an increased risk of Down’s syndrome. This study was
small (827 women), but led to further research into the use of NT
scanning and its value when combined with serum tests. Other
first trimester ultrasound markers, such as absent nasal bone, ab-
normal ductus venosus flow velocity and tricuspid regurgitation,
have also been investigated.
In addition to serum and ultrasound markers for Down’s syn-
drome, work has been carried out looking at urinary markers.
These markers include invasive trophoblast antigen, ß-core frag-
ment, free ßhCGand total hCG (Cole 1999). There is controversy
about their value (Wald 2003a).
Screening and parental choice
Antenatal screening is used for several reasons (Alfirevic 2004), but
the most important is to enable parental choice regarding preg-
nancymanagement and outcome. Before awoman and her partner
opt to have a screening test, they need to be fully informed about
the risks, benefits and possible consequences of such a test. This
includes the choices they may have to face should the result show
that the woman has a high risk of carrying a baby with Down’s
syndrome and the implications of both false positive and false neg-
ative screening tests. They need to be informed of the risk of a
miscarriage due to invasive diagnostic testing, and the possibility
that a miscarried fetus may be chromosomally normal. If, follow-
ing invasive diagnostic testing, the fetus is shown to have Down’s
syndrome, further decisions need to be made about continuation
or termination of the pregnancy, the possibility of adoption and
finally, preparation for parenthood. Equally, if a woman has a test
that shows she is at a low risk of carrying a fetus with Down’s
syndrome, it does not necessarily mean that the baby will be born
with a normal chromosomal make up. This possibility can only be
excluded by an invasive diagnostic test (Alfirevic 2003). The deci-
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sions that may be faced by expectant parents inevitably engender
a high level of anxiety at all stages of the screening process, and the
outcomes of screening can be associated with considerable physi-
cal and psychological morbidity. No screening test can predict the
severity of problems a person with Down’s syndrome will have.
Index test(s)
This review examined serum screening tests used in the first and
second trimester of pregnancy (up to 24 weeks’ gestation) with
and without first trimester ultrasound tests (up to 14 weeks’ ges-
tation). The review examined the following individual markers;
NT measurement in the first trimester, ADAM 12, AFP, uE3, to-
tal hCG, free βhCG, Inhibin A and PAPP-A. These markers can
be used individually, in combination with age, and can also be
used in combination with each other. The risks are calculated by
comparing a woman’s test result for each marker with values for an
unaffected population, and multiplying this with her age-related
risk. Where several markers are combined, risks are computed us-
ing risk equations (often implemented in commercial software)
that take into account the correlational relationships between the
different markers and marker distributions in affected and unaf-
fected populations.
Stepwise testing allows for triage of women into risk categories
at two stages. Women found to be very high risk at the end of
first trimester screening are offered invasive testing, whereas those
women deemed to be lower risk are then screened again in the
second trimester and a further overall risk is calculated once both
stages of the test are completed.
Contingent screening is similar, however at the completion of
first trimester screening women are classified into three groups -
high risk, medium risk and low risk. High risk women are offered
invasive testing at this stage, low risk women undergo no further
screening and medium risk women are offered second trimester
serum tests and calculation of a further overall risk once both stages
of the test are completed.
Alternative test(s)
Down’s syndrome can be detected during pregnancy with invasive
diagnostic tests such as amniocentesis or CVS, with or without
prior screening. The ability to determine fetal chromosomal make
up (also known as a karyotype) from amniotic fluid samples was
demonstrated in 1966 by Steele and Breg (Steele 1966), and the
first antenatal diagnosis of Down’s syndrome was made in 1968
(Valenti 1968). Amniocentesis is an invasive procedure which in-
volves taking a small sample of the amniotic fluid (liquor) sur-
rounding the baby, using a needle which goes through the abdom-
inal wall into the uterus, and is usually performed after 15 weeks’
gestation. CVS involves taking a sample of the placental tissue
using a needle which goes through the abdominal wall and uterus
or a cannula through the cervix. It is usually performed between
10 and 13 weeks’ gestation. Amniocentesis and CVS are both
methods of obtaining fetal chromosomes material, which are then
used to diagnose Down’s syndrome. Both tests use ultrasound
scans to guide placement of the needle. Amniocentesis carries a
risk of miscarriage in the order of 1%; transabdominal CVS may
carry a similar risk (Alfirevic 2003). Recent developments in the
use of cell-free fetal DNA detection in maternal serum are paving
the way for non-invasive diagnosis of Down’s syndrome and other
trisomies, however these tests were not used as reference standards
in any of the studies examined.
There are many different screening tests which are available and
offered which are the subject of additional Cochrane reviews
and there are other reviews looking at this area. Tests being as-
sessed in the other Cochrane reviews include first trimester serum
tests (Alldred 2015); urine tests (Alldred 2015a); second trimester
serum markers (Alldred 2012); and first trimester ultrasound tests
alone, or in combination with first trimester serum tests (in press).
Second trimester ultrasound markers have been assessed in a pre-
vious systematic review (Smith-Bindman 2001).
Rationale
This is one of a suite of Cochrane reviews, the aim of which is to
identify all screening tests for Down’s syndrome used in clinical
practice, or evaluated in the research setting, in order to try to iden-
tify the most accurate test(s) available, and to provide clinicians,
policy makers and women with robust and balanced evidence on
which to base decisions about interpreting test results and imple-
menting screening policies to triage the use of invasive diagnostic
testing. The full set of reviews is described in the generic protocol
(Alldred 2010).
A systematic review of second trimester ultrasound markers for
detection of Down’s syndrome concluded that nuchal fold thick-
ening may be useful in detectingDown’s syndrome, but that it was
not sensitive enough to be used as a screening test (Smith-Bindman
2001). The review concluded that other second trimester ultra-
sound markers did not usefully distinguish between Down’s syn-
drome and pregnancies withoutDown’s syndrome. There has been
no systematic review and meta-analysis of serum, urine and first
trimester ultrasound markers to enable rigorous and robust con-
clusions to be made about the diagnostic accuracy of available
Down’s syndrome screening tests.
The topic has been split into several different reviews to allow for
greater ease of reading and greater accessibility of data, and also to
allow the reader to focus on separate groups of tests, for example,
first trimester serum tests alone, first trimester ultrasound alone,
first trimester serumandultrasound, second trimester serumalone,
first and second trimester serum, combinations of serum and ul-
trasound markers and urine markers alone. An overview review
will compare the best tests, focusing on commonly used strategies,
from each of these groups to give comparative results between the
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best tests in the different categories. This review is written with
the global perspective in mind, rather than to conform with any
specific local or national policy, as not all tests will be available in
all areas where screening for Down’s syndrome is carried out.
O B J E C T I V E S
The aim of this review was to estimate and compare the accu-
racy of first and second trimester serum markers with and with-
out first trimester ultrasound markers for the detection of Down’s
syndrome in the antenatal period, as combinations of markers.
Individual markers are described in the other reviews belonging to
this suite. Accuracy is described by the proportion of fetuses with
Down’s syndrome detected by screening before birth (sensitivity
or detection rate) and the proportion of women with a low risk
(normal) screening test result who subsequently had a baby unaf-
fected by Down’s syndrome (specificity).
Investigation of sources of heterogeneity
We planned to investigate whether a uniform screening test is suit-
able for all women, or whether different screening methods are
more applicable to different groups, defined by advanced mater-
nal age, ethnic groups and aspects of the pregnancy and medical
history such as multiple pregnancy, diabetes and family history
of Down’s syndrome. We also considered whether there existed
evidence of overestimation of test accuracy in studies evaluating
risk equations in the derivation sample rather than in a separate
validation sample.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies in which all women from a given popula-
tion had one or more index test(s) compared to a reference stan-
dard. Both consecutive series and diagnostic case-control study
designs were included. Randomised trials where individuals were
randomised to different screening strategies and all verified us-
ing a reference standard were also eligible for inclusion. Studies
in which test strategies were compared head-to-head either in the
same women, or between randomised groups were identified for
inclusion in separate comparisons of test strategies. Studies were
excluded if they included less than five Down’s syndrome cases, or
more than 20% of participants were not followed up.
Participants
Pregnant women up to 24 weeks’ gestation confirmed by ultra-
sound, who had not undergone previous testing for Down’s syn-
drome in their pregnancy were eligible. Studies were included if
the pregnant womenwere unselected, or if they represented groups
with increased risk of Down’s syndrome, or difficulty with con-
ventional screening tests including maternal age greater than 35
years old, multiple pregnancy, diabetes mellitus and family history
of Down’s syndrome.
Index tests
The following index tests were examined; nuchal translucency
(NT) scanning, ADAM12, AFP, uE3,total hCG, free βhCG, In-
hibin A, PAPP-A, and combinations of these markers with mater-
nal age. Combinations without maternal age were excluded.
We looked at comparisons of tests in isolation and in various
combinations. All strategies included first and second trimester
serum tests, and some included additional first trimester ultra-
sound markers. The maximum number of markers in any one test
was seven, in combination with maternal age.
Where testswere used in comparisonwe looked at the performance
of test comparisons according to predicted probabilities computed
using risk equations and dichotomised into high risk and low risk
(and medium risk, where applicable).
Target conditions
Down’s syndrome in the fetus due to trisomy, translocation or
mosaicism.
Reference standards
Weconsidered several reference standards, involving chromosomal
verification and postnatal macroscopic inspection.
Amniocentesis and chorionic villus sampling (CVS) are inva-
sive chromosomal verification tests undertaken during pregnancy.
They are highly accurate, but the process carries a 1% miscarriage
rate, and therefore they are only used in pregnancies considered
to be at high risk of Down’s, or at the mother’s request. All other
types of testing (postnatal examination, postnatal karyotyping,
birth registers and Down’s syndrome registers) are based on infor-
mation available at the end of pregnancy. The greatest concern is
not their accuracy, but the loss of the pregnancy to miscarriage
between the serum test and the reference standard. Miscarriage
with cytogenetic testing of the fetus is included in the reference
standard where available. We anticipated that older studies, and
studies undertaken in older women are more likely to have used
invasive chromosomal verification tests in all women.
Studies undertaken in younger women and more recent studies
were likely to use differential verification as they often only used
prenatal karyotypic testing on fetuses considered screen positive/
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high risk according to the screening test; the reference standard for
most unaffected infants being observing a phenotypically normal
baby. Although the accuracy of this combined reference standard
is considered high, it is methodologically a weaker approach as
pregnancies that miscarry between the index test and birth are
likely to be lost from the analysis, and miscarriage is more likely
to occur in Down’s than normal pregnancies. We investigated the
impact of the likely missing false negative results in sensitivity
analyses.
Search methods for identification of studies
We used one generic search strategy to identify studies for all
reviews in this series.
Electronic searches
We applied a sensitive search strategy to search the follow-
ing databases using the text words and MeSH terms detailed
in Appendix 1, adapting the search strategy for each different
database.
The following databases were searched.
1. MEDLINE via OVID (1980 to 25 August 2011)
2. Embase via Dialog Datastar (1980 to 25 August 2011)
3. BIOSIS via EDINA (1985 to 25 August 2011)
4. CINAHL via OVID (1982 to 25 August 2011)
5. The Database of Abstracts of Reviews of Effectiveness (25
August 2011)
6. MEDION (25 August 2011)
7. The Database of Systematic Reviews and Meta-Analyses in
Laboratory Medicine (www.ifcc.org/) (25 August 2011)
8. The National Research Register (Archived 2007)
9. Health Services Research Projects in Progress database (
HSRPROJ) (25 August 2011)
The search strategy combined three sets of search terms (see
Appendix 1). The first set was made up of named tests, general
terms used for screening/diagnostic tests and statistical terms.Note
that the statistical terms were used to increase sensitivity and were
not used as a methodological filter to increase specificity. The sec-
ond set was made up of terms that encompass Down’s syndrome
and the third set made up of terms to limit the testing to pregnant
women. All termswithin each set were combinedwith the Boolean
operator OR and then the three sets were combined using AND.
The terms used were a combination of subject headings and free-
text terms. The search strategy was adapted to suit each database
searched.
We attempted to identify cumulative papers that reported data
from the same data set, and contacted authors to obtain clarifi-
cation of the overlap between data presented in these papers, in
order to prevent data from the same women being analysed more
than once.
Searching other resources
In addition, we examined references cited in studies identified as
being potentially relevant, and those cited by previous reviews.
We contacted authors of studies where further information was
required.
We carried out forward citation searching of relevant items, us-
ing the search strategy in ISI citation indices, Google scholar and
Pubmed ‘related articles’.
We did not apply language restrictions to the search.
Data collection and analysis
Selection of studies
Two review authors screened the titles and abstracts (where avail-
able) of all studies identified by the search strategy. Full-text ver-
sions of studies identified as being potentially relevant were ob-
tained and independently assessed by two review authors for in-
clusion, using a study eligibility screening pro forma according to
the pre-specified inclusion criteria. Any disagreement between the
two review authors was settled by consensus, or where necessary,
by a third party.
Data extraction and management
A data extraction form was developed and piloted using a subset
of 20 identified studies (from all identified studies in this suite of
reviews). Two review authors independently extracted data, and
where disagreement or uncertainty existed, a third review author
validated the information extracted.
Data on eachmarker were extracted as binary test positive/test neg-
ative results for Down’s and non-Down’s pregnancies, with a high
risk result - as defined by each individual study - being regarded as
test positive (suggestive or diagnostic of Down’s syndrome), and
a low risk result being regarded as test negative (suggestive of ab-
sence of Down’s syndrome). Where results were reported at several
thresholds, we extracted data at each threshold.
We noted those in special groups that posed either increased risk of
Down’s syndrome or difficulty with conventional screening tests
including maternal age greater than 35 years old, multiple preg-
nancy, diabetes mellitus and family history of Down’s syndrome.
Assessment of methodological quality
Weused amodified version of theQUADAS tool (Whiting 2003),
a quality assessment tool for use in systematic reviews of diagnostic
accuracy studies, to assess the methodological quality of included
studies. We anticipated that a key methodological issue would be
the potential for bias arising from the differential use of invasive
testing and follow-up for the reference standard according to in-
dex test results, bias arising due to higher loss to miscarriage in
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false negatives than true negatives. We chose to code this issue
as originating from differential verification in the QUADAS tool:
we are aware that it could also be coded under delay in obtaining
the reference standard, and reporting of withdrawals. We omit-
ted the QUADAS item assessing quality according to length of
time between index and reference tests, as Down’s syndrome is
either present or absent rather than a condition that evolves and
resolves, and disregarding the differential reference standard issue
thus any length of delay is acceptable. Two review authors assessed
each included study separately. Any disagreement between the two
authors was settled by consensus, or where necessary, by a third
party. Each item in the QUADAS tool was marked as ‘yes’, ‘no’ or
‘unclear’, and scores were summarised graphically. We did not use
a summary quality score.
QUADAS criteria included the following 10 questions.
1. Was the spectrum of women representative of the women
who will receive the test in practice? (Criteria met if the sample
was selected from a wide range of childbearing ages, or selected
from a specified ‘high risk’ group such as over 35s, family history
of Down’s syndrome, multiple pregnancy or diabetes mellitus,
provided all affected and unaffected fetuses included that could
be tested at the time point when the screening test would be
applied; criteria not met if the sample taken from a select or
unrepresentative group of women (i.e. private practice), was an
atypical screening population or recruited at a later time point
when selection could be affected by selective fetal loss.)
2. Is the reference standard likely to correctly classify the target
condition? (Amniocentesis, chorionic villus sampling, postnatal
karyotyping, miscarriage with cytogenetic testing of the fetus, a
phenotypically normal baby or birth registers are all regarded as
meeting this criteria.)
3. Did the whole sample or a random selection of the sample
receive verification using a reference standard of diagnosis?
4. Did women receive the same reference standard regardless
of the index test result?
5. Was the reference standard independent of the index test
result (i.e. the index test did not form part of the reference
standard)?
6. Were the index test results interpreted without knowledge
of the results of the reference standard?
7. Were the reference standard results interpreted without
knowledge of the results of the index test?
8. Were the same clinical data (i.e. maternal age and weight,
ethnic origin, gestational age) available when test results were
interpreted as would be available when the test is used in practice?
9. Were uninterpretable/intermediate test results reported?
10. Were withdrawals from the study explained?
Statistical analysis and data synthesis
We initially examined each test or test strategy at each of the com-
mon risk thresholds used to define test positivity by plotting esti-
mates of sensitivity and specificity from each study on forest plots
and in receiver operating characteristic (ROC) space. Test strate-
gies were selected for further investigation if they were evaluated
in four or more studies or, if there were three or fewer studies,
but the individual study results indicated performance likely to be
superior to a sensitivity of 70% and specificity of 90%.
Estimation of average sensitivity and specificity
The analysis for each test strategy was undertaken first, by restrict-
ing to studies that reported a common threshold to estimate av-
erage sensitivity and specificity for each test at each threshold. Al-
though data on all thresholds were extracted, we present only key
common thresholds close to risks of 1:384, 1:250 and the 5% false
positive rate (FPR), unless other thresholds were more commonly
reported. Where combinations of tests were used in a risk score,
we extracted the result for the test combination using the risk score
and not the individual components that made up the test.
Meta-analyses were undertaken using hierarchical summary ROC
(HSROC) models, which included estimation of random-effects
in accuracy and threshold parameters when there were four or
more studies. Otherwise, average sensitivity and specificity values
were computed by using univariate random-effects logistic regres-
sion models to average logit sensitivity and logit specificity sep-
arately because of insufficient number of studies to reliably es-
timate all the parameters in the HSROC model. It is common
in this field for studies to report sensitivity for a fixed specificity
(usually a 5% FPR). This removes the requirement to account for
the correlation between sensitivity and specificity across studies by
using a bivariate meta-analytical method since all specificities are
the same value. Thus, at a fixed specificity value, logit sensitivities
were pooled using a univariate random-effects model. This model
was further simplified to a fixed-effectmodel when there were only
two or three studies and heterogeneity was not observed on the
SROC plot. All analyses were undertaken using the NLMIXED
procedure in SAS (version 9.2; SAS Institute, Cary, NC) and the
xtmelogit command in Stata version 11.2 (Stata-Corp, College
Station, TX, USA).
Comparisons between tests
Comparisons between tests were first made utilising all available
studies, selecting one threshold from each study to estimate a sum-
mary ROC curve without restricting to a common threshold. The
threshold was chosen for each study according to the following
order of preference: a) the risk threshold closest to one in 250; b)
a multiples of the median (MoM) or presence/absence threshold;
c) the performance closest to a 5% FPR or 95th percentile. The
5% FPR was chosen as a cut-off point as this is the cut-off most
commonly reported in the literature. The analysis that used all
available studies was performed by including the six most evalu-
ated test strategies in a single HSROCmodel. Themodel included
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two indicator terms for each test to allow for differences in accu-
racy and threshold. As there were few studies for each test, a single
summary ROC shape parameter was included in the model such
that the fitted summary ROC curves did not cross. An estimate
of the sensitivity of each test for a 5% FPR was derived from the
summary ROC curve, and associated confidence intervals were
obtained using the delta method.
Direct comparisons between tests were based on results of very
few studies, and were analysed using a fixed-effect HSROCmodel
with symmetrical underlying summary ROC curves because the
number of studies was insufficient to estimate between-study het-
erogeneity in accuracy and threshold or asymmetry in the shape
of the summary ROC curves. A separate model was used to make
each pair-wise comparison. Comparisons between tests were as-
sessed by using likelihood ratio tests to test if the differences in
accuracy were statistically significant or not. The differences were
expressed as relative diagnostic odds ratios and were reported with
95% confidence intervals. As studies rarely report data cross-clas-
sified by both tests for Down’s and normal pregnancies, the analyt-
ical method did not take full account of the pairing of test results,
but the restriction to direct head-to-head comparisons should have
removed the potential confounding of test comparisons with other
features of the studies. The strength of evidence for differences in
performance of test strategies relied on evidence from both the
direct and indirect comparisons.
Investigations of heterogeneity
If there were 10 or more studies available for a test, we planned to
investigate heterogeneity by adding covariate terms to theHSROC
model to assess the effect of a covariate on accuracy and threshold.
Sensitivity analyses
Mothers with pregnancies identified as high risk for Down’s syn-
drome by ultrasound and serum testing are often offered immedi-
ate definitive testing by amniocentesis, whereas those considered
low risk are assessed for Down’s syndrome by inspection at birth.
Such delayed and differential verification will introduce bias, most
likely through there being greater loss to miscarriage in theDown’s
syndrome pregnancies that were not detected by the ultrasound
and serum testing (the false negative diagnoses). Testing and de-
tection of miscarriages is impractical in many situations, and no
clear data are available on themagnitude of these miscarriage rates.
To account for the possible bias introduced by such a mechanism,
we planned to perform sensitivity analyses by increasing the per-
centage of false negatives in studies where delayed verification in
test negatives occurred (Mol 1999). We planned to incrementally
increase the percentage from 10% to 50%, the final value repre-
senting a scenario where a third of more Down’s pregnancies than
normal pregnancies were likely to miscarry, thought to be higher
than the likely value. We intended to conduct the sensitivity anal-
yses on the analysis investigating the effect of maternal age on test
sensitivity.
Assessment of reporting bias
Assessment of reporting bias was not performed.
R E S U L T S
Results of the search
The search for the whole suite of reviews identified a total of
15,394 papers, once the results from each bibliographic database
were combined and duplicates were removed. After screening out
obviously irrelevant papers based on their title and abstract, 1145
papers remained and we obtained full-text copies for formal assess-
ment of eligibility. From these a total of 269 papers were deemed
eligible and were included in the suite of reviews. A total of 22
studies (reported in 25 publications) were included in this review
of first and second trimester serum screening, with and without ul-
trasound, involving 228,615 pregnancies including 1067 Down’s
syndrome pregnancies.
A total of 32 different test strategies combinations were evalu-
ated in the 22 studies. The tests were produced from combina-
tions of eight different tests, with and without maternal age; first
trimester nuchal translucency (NT) and the serum markers AFP,
uE3, total hCG, free βhCG, Inhibin A, PAPP-A and ADAM 12.
We examined tests combining first and second trimester mark-
ers with or without ultrasound as complete tests, and also exam-
ined stepwise and contingent strategies. The studies evaluated the
following serum-only tests: one single test without maternal age,
and one septuple test, two sextuple tests, five quintuple tests, two
quadruple tests and two triple test in combination with maternal
age. Serum and ultrasound markers were evaluated in combina-
tion with maternal age: one study of seven markers, three studies
of six markers, four studies of five markers, four studies of four
markers and two studies of three markers. In addition, there were
two contingent and three stepwise test strategies. Twelve of the
22 studies only evaluated the performance of a single test or test
strategy, five compared two tests, two compared three tests, two
compared five tests, and one compared 20 tests (Wald 2003b).
The following test combinations were themost evaluated andwere
each evaluated in four studies.
Six markers
• First trimester NT, first trimester PAPP-A , second trimester
free ßhCG, second trimester uE3, second trimester AFP, second
trimester Inhibin A, and maternal age (four studies; 40,348
women including 266 Down’s syndrome pregnancies)
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Four markers
• First trimester PAPP-A, second trimester total hCG, second
trimester uE3, second trimester AFP and maternal age (four
studies; 2474 women, including 236 Down’s syndrome
pregnancies)
• First trimester NT, second trimester total hCG, second
trimester uE3, second trimester AFP and maternal age (four
studies; 13,708 women, including 136 Down’s syndrome
pregnancies)
Three markers
• First trimester NT, second trimester total hCG, second
trimester AFP and maternal age (four studies; 22,793 women,
including 135 Down’s syndrome pregnancies)
Of the remaining 28 test combinations, two were evaluated in
three studies, eightwere evaluated in two studies and the remaining
18 in single studies only.
Methodological quality of included studies
Methodological quality of the studies was judged to be high in
half of the categories (Figure 1). Due to the nature of testing
for Down’s syndrome screening and the potential side effects of
invasive testing, differential verification is almost universal in the
general screening population, asmost women whose screening test
result is defined as low risk will have their screening test verified
at birth, rather than by invasive diagnosis in the antenatal period.
Additionally, it was not possible to ascertain from the included
studies whether or not the results of index tests and reference
standards were blinded. It would be difficult to blind clinicians
performing invasive diagnostic tests (reference standards) to the
index test result, unless all women received the same reference
standard, which would not be appropriate in most scenarios. Any
biases secondary to a lack of clinician blinding are likely to be
minimal.
Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Although not explicitly stated, most studies seemed to indicate
100% follow-up. Inevitably there will be losses to follow-up due
to, for example, women moving out of the area of a study. It was
therefore difficult to measure reporting of uninterpretable tests
and hence reporting of withdrawals. Studies usually accounted for
these and it is unlikely to have introduced significant bias. There
was definitely under-ascertainment of miscarriage, and very few
papers accounted for miscarriage or performed tissue karyotyping
in pregnancies resulting in miscarriage. Some studies attempted to
adjust for predicted miscarriage rate and the incidence of Down’s
syndrome in this specific population, but most did not. We have
not attempted to adjust for expected miscarriage rate in this re-
view. This issue has the potential to have more influence with first
trimester testing due to a higher miscarriage rate per se in this
trimester.
Some studies that provided estimates of risk using multivariable
equations used the same data set to evaluate performance of the
risk equation as was used to derive the equation. This is often
thought to lead to over-estimation of test performance.
Findings
The results for the six most evaluated test strategies are presented
in Summary of findings 1. Additional information is provided
below.
1) First trimester nuchal translucency, first trimester
PAPP-A, second trimester free ßhCG, second
trimester uE3, second trimester AFP, second
trimester Inhibin A, and maternal age
Four studies (Aagaard-Tillery 2009; Bestwick 2010; Wald 2003b;
Wald 2009) evaluated this test strategy. The studies included
40,348 women in whom 266 pregnancies were affected by
Down’s syndrome. Over half the data were provided by Bestwick
2010 (22,746 women, including 106 Down’s syndrome pregnan-
cies). Studies presented data for different cut-points but three
(Aagaard-Tillery 2009; Bestwick 2010; Wald 2003b) of the four
studies also presented data for a 5% false positive rate (FPR). At
a fixed cut-point of 5% FPR on the summary ROC curve, the
estimated sensitivity based on all four studies was 92% (95% con-
fidence interval (CI) 88 to 95).
2) First trimester PAPP-A, second trimester total
hCG, second trimester uE3, second trimester AFP
and maternal age
Four studies (Baviera 2010; Wald 2003b; Wright 2010 FASTER
trial; Wright 2010 North York) evaluated this test strategy. The
studies included 2474 women in whom 236 pregnancies were af-
fected by Down’s syndrome. Most of the data were provided by
Wald 2003b (118 women, including 98 Down’s syndrome preg-
nancies). Studies presented data for cut-points of 5% FPR (two
studies Baviera 2010; Wald 2003b) and 1:250 risk (two studies
Wright 2010 FASTER trial; Wright 2010 North York). At a fixed
cut-point of 5% FPR, the estimated sensitivity was 85% (95% CI
78 to 89).
3) First trimester nuchal translucency, second
trimester total hCG, second trimester uE3, second
trimester AFP and maternal age
Results for this test strategywere derived from four studies (Babbur
2005; Herman 2002; Schuchter 2001;Wald 2003b) and included
13,708 women in whom 136 pregnancies were known to be af-
fected by Down’s syndrome. Schuchter 2001 contributed 9342
pregnancies to the data. Studies presented data for cut-points of
5% FPR (two studies: Schuchter 2001; Wald 2003b) and 1:250
risk (two studies:Babbur 2005; Herman 2002). At a fixed cut-
point of 5% FPR, the estimated sensitivity was 86% (95% CI 78
to 92).
4) First trimester nuchal translucency, second
trimester total hCG, second trimester AFP and
maternal age
Results were derived from four studies (Audibert 2001; Benattar
1999; Lam 2002; Wald 2003b) and included 22,793 women in
whom 135 pregnancies were known to be affected by Down’s
syndrome. Lam 2002 contributed 16,237 pregnancies to the data.
Studies presented data for cut-points of 5%FPR (two studies: Lam
2002; Wald 2003b;) and 1:250 risk (two studies: Audibert 2001;
Benattar 1999). At a fixed cut-point of 5% FPR, the estimated
sensitivity was 85% (CI 77 to 91).
5) Other test combinations
Of the 28 test combinations evaluated in three or fewer studies,
25 test combinations demonstrated estimated sensitivities of at
least 70% and estimated specificities of more than 90%. Sixteen
of these were evaluated in single studies only (see Summary of
findings 2). Of the remaining nine test combinations evaluated in
two or three studies, data were pooled for the following six tests.
• First trimester PAPP-A and second trimester total hCG,
uE3, AFP and PAPP-A, and maternal age evaluated in two
studies (Wright 2010 FASTER trial; Wright 2010 North York)
estimated a sensitivity of 78% (CI 66 to 86) and specificity of
98% (CI 96 to 99) at a cut-point of 1:200 risk.
• First trimester PAPP-A and second trimester total hCG,
uE3, AFP and inhibin A, and maternal age evaluated in three
studies (Malone 2005; Palomaki 2006; Wald 2003b) estimated a
sensitivity of 87% (CI 81 to 91) at a cut-point of 5% FPR.
• First trimester PAPP-A and total hCG, and second
trimester total hCG, uE3 and AFP evaluated in two studies
(Wright 2010 FASTER trial; Wright 2010 North York)
estimated a sensitivity of 80% (CI 68 to 88) and specificity of
97% (CI 94 to 98) at a cut-point of 1:200 risk.
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• First trimester PAPP-A and uE3, and second trimester
total hCG, uE3 and AFP evaluated in two studies (Wright 2010
FASTER trial; Wright 2010 North York) estimated a sensitivity
of 80% (CI 68 to 88) and specificity of 96% (CI 93 to 98) at a
cut-point of 1:200 risk.
• First trimester NT and second trimester free ßhCG and
AFP, and maternal age evaluated in two studies (Rozenberg
2002; Wald 2003b) estimated a sensitivity of 83% (CI 70 to 91)
at a cut-point of 5% FPR.
• First trimester NT and PAPP-A, and second trimester
total hCG, uE3, AFP and Inhibin A, and maternal age
evaluated in three studies (Malone 2005; Wald 2003b; Wald
2009) estimated a sensitivity of 95% (CI 90 to 97) at a cut-point
of 5% FPR.
Comparative analysis of the six selected test
strategies
For each test, we obtained the detection rate (sensitivity) for a
fixed false positive rate (FPR) (1-specificity), a metric which is
commonly used in Down’s syndrome screening to describe test
performance. We chose to estimate detection rates at a 5% FPR
in common with much of the literature. Figure 2 shows point es-
timates of the detection rate (and their 95% CIs) at a 5% FPR
based on all available data for the six test strategies; the test strate-
gies are ordered according to decreasing detection rates. The plot
shows that all six test strategies have detection rates of 85% and
above. The six marker maternal age-adjusted combination of first
trimester NT and PAPP-A with second trimester total hCG, uE3,
AFP and inhibin A showed the highest detection rate with an es-
timated detection rate of 95% (95% CI 90 to 97) based on data
from three studies with 184 affected cases out of a total of 39,670
pregnancies. The next best performing strategy was a test combi-
nation with the same markers except that it included free ßhCG
instead of total hCG. For this combination, the estimated detec-
tion rate was 92% (95% CI 88 to 95) based on data from four
studies with 266 affected cases out of a total of 40,348 pregnan-
cies. The remaining four test strategies showed similar detection
rates.
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Figure 2. Detection rates (% sensitivity) at a 5% false positive rate for the six most evaluated test strategies
(estimates from summary ROC curves).A = First trimester NT and PAPP-A , second trimester total hCG,
uE3, AFP and inhibin A;B = First trimester NT and PAPP-A , second trimester free ßhCG, uE3, AFP and
inhibin A; C = First trimester PAPP-A , second trimester total hCG, uE3, AFP and inhibin A; D = First
trimester NT, second trimester total hCG, uE3 and AFP; E = First trimester NT, second trimester total hCG
and AFP; and F = First trimester PAPP-A , second trimester total hCG, uE3 and AFP.All test combinations
include maternal age. Each circle represents the summary sensitivity for a test strategy at a 5% false positive
rate. The size of each circle is proportional to the number of Down’s cases. The estimates are shown with 95%
confidence intervals. The test strategies are ordered on the plot according to decreasing detection rate. The
number of studies, cases and women included for each test strategy are shown on the horizontal axis.
The strength of evidence for differences in the diagnostic perfor-
mance of the six test strategies relied on evidence from both direct
and indirect comparisons. Table 1 shows pair-wise direct com-
parisons (head-to-head) where studies were available. Such com-
parisons are regarded as providing the strongest evidence as dif-
ferences between tests are unconfounded by study characteristics.
The table shows the number of studies (K), the ratios of diagnos-
tic odds ratios (DORs) with 95% CI and P values for each test
comparison. There were no statistically significant differences in
accuracy between any pair of tests. However, all comparisons in
this table were based on one or two studies and so are unlikely to
be powered to detect differences in accuracy.
Table 2 shows the same comparisons made using all available data.
Results are generally in agreementwith the direct comparisons, and
in addition, showed some statistically significance differences (P <
0.05) suggesting that the six marker maternal age-adjusted com-
bination of first trimester NT and PAPP-A with second trimester
total hCG, uE3, AFP and inhibin A outperformed all the other
test strategies except when compared with a similar strategy that
included free ßhCG instead total hCG.
Comparison of integrated, contingent and stepwise
strategy for a septuple combination of serum tests
and first trimester nuchal translucency
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Table 3 shows the results of two studies that assessed integrated,
contingent or stepwise strategies. Integrated testing involves per-
forming first trimester NT, PAPP-A and free ßhCG, and second
trimester uE3, AFP, total hCG and inhibin A, without disclosure
of the first trimester result. The strategy was evaluated in one study
(Malone 2005) that reported a 94% sensitivity (95% CI 87 to 98)
and 89% specificity (95% CI 89 to 89) for a cut-point of 1:150.
In one study (Cuckle 2008), stepwise and contingent tests were
compared in the same patient population, with similar detection
rates (stepwise 91% (95% CI 84 to 97); contingent 92% (95%
CI 82 to 96)) and identical false positive rates of 5% at cut-points
of 1:270.
The perceived advantages of the stepwise and contingent meth-
ods are that women deemed to be very high risk are offered inva-
sive testing in the first trimester, allowing for earlier detection of
Down’s syndrome and subsequent management. Termination of
pregnancy in the first trimester of pregnancy is safer than at later
gestations. With contingent screening, where women are deemed
to be low risk with a numerical risk of < 1:1500, no further testing
is offered, and it does not appear to adversely affect the detection
rate. In those women who are considered to be intermediate risk,
additional second trimester serum tests may detect cases of Down’s
syndrome that would have been missed. Of note, in the study
evaluated, all of the women found to have a risk of > 1:30 on first
trimester screening were found to be high risk upon completion
of the full contingent screening package. This type of screening
may facilitate patient decision making, however further evaluation
needs to be carried out.
It is difficult tomake a comparison between the integrated method
and the stepwise and contingent methods in practical terms, as
the non-disclosure of the first trimester result means that women
would not be offered earlier diagnostic testing. More information
is required about all three methods of testing in order to make a
recommendation, as not all methods will be acceptable to women.
Investigation of heterogeneity and sensitivity analyses
The key characteristics of the 22 included studies is summarised
in Table 4 with further details available in the Characteristics of
included studies table. None of the tests was evaluated by 10 or
more studies and so we were unable to investigate the effect of any
potential source of heterogeneity. The planned sensitivity analyses
were also not possible.
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Summary of findings
Test strategy (with ma-
ternal age)
Studies Women (cases) Sensitivity (95% CI) at a 5% FPR Test*
First trimester PAPP-A
and second trimester
total hCG, uE3 and AFP
4 2474 (236) 85 (78, 89) P = 0.014
First trimester PAPP-A
and second trimester
total hCG, uE3, AFP and
inhibin A
3 35,361 (217) 87 (81, 91)
First trimester NT and
second trimester total
hCG and AFP
4 22,793 (135) 85 (77, 91)
First trimester NT and
second trimester total
hCG, uE3 and AFP
4 13,708 (136) 86 (78, 92)
First trimester NT and
PAPP-A, and second
trimester total hCG,
uE3, AFP and inhibin A
3 39,670 (184) 95 (90, 97)
First trimester NT and
PAPP-A, and second
trimester f ree ßhCG,
uE3, AFP and inhibin A
4 40,348 (266) 92 (88, 95)
* Likelihood rat io test for the dif ference in accuracy between the six test strategies compared in a single meta-analyt ic model
AFP = alpha-fetoprotein; ßhCG = beta human chorionic gonadotrophin; FPR = false posit ive rate;hCG = human chorionic
gonadotrophin; NT = nuchal translucency; PAPP-A = pregnancy-associated plasma protein-A; uE3 = unconjugated oestriol
CI = conf idence interval
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Test Studies Women (cases) Sensitivity* (95% CI) Specificity* (95% CI) Threshold
Without maternal age and
ultrasound
Single tests
ADAM 12 second trimester
to f irst trimester rat io
1 579 (17) 53 (28, 77) 95 (93, 97) 5% FPR
With maternal age and
without ultrasound
Triple tests
First trimester PAPP-A and
second trimester total hCG
and AFP
1 1188 (98) 83 (74, 90) 95 (93, 96) 5% FPR
First trimester PAPP-A and
second trimester f ree ßhCG
and AFP
2 2197 (94) 83 to 85 94 to 95 5% FPR, 1:300 risk
Quadruple tests
First trimester PAPP-A and
second trimester f ree ßhCG,
uE3 and AFP
1 1188 (98) 86 (77, 92) 95 (93, 96) 5% FPR
Quintuple tests
First trimester PAPP-A and
second trimester f ree ßhCG,
uE3, AFP and inhibin A
1 1188 (98) 90 (82, 95) 95 (93, 96) 5% FPR
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First trimester PAPP-A and
second trimester total hCG,
uE3, AFP and PAPP-A
2 707 (121) 78 (66, 86) 98 (96, 99) 1:200 risk
First trimester PAPP-A and
total hCG, and second
trimester total hCG, uE3 and
AFP
2 707 (121) 80 (68, 88) 97 (94, 98) 1:200 risk
First trimester PAPP-A and
uE3, and second trimester
total hCG, uE3 and AFP
2 707 (121) 80 (68, 88) 96 (93, 98) 1:200 risk
Sextuple tests
First trimester AFP, f ree
ßhCG and uE3, and second
trimester total hCG, uE3 and
AFP
1 12,339 (34) 82 (65, 93) 94 (93, 94) 1:250 risk
First trimester PAPP-A and
second trimester total hCG,
uE3, AFP, inhibin A and
PAPP-A
1 540 (32) 84 (67, 95) 96 (94, 98) 1:250 risk
Septuple tests
First trimester PAPP-A, to-
tal hCGand uE3,and second
trimester total hCG, uE3,
AFP and PAPP-A
2 707 (121) 49 (36, 61) 98 (96, 99) 1:200 risk
With maternal age and ul-
trasound
Triple tests
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First trimester NT and sec-
ond trimester f ree ßhCGand
AFP
2 6616 (105) 83 (70, 91) 95 5% FPR
Quadruple tests
First trimester NT and sec-
ond trimester f ree ßhCG,
uE3 and AFP
1 1110 (85) 88 (79, 94) 95 (94, 96) 5% FPR
First trimester
NT and PAPP-A, and second
trimester total hCG and AFP
1 1110 (85) 91 (82, 96) 95 (94, 96) 5% FPR
First
trimester NT and PAPP-A,
and second trimester f ree
ßhCG and AFP
2 3400 (93) 88 to 91 95 to 98 5% FPR, 1:300 risk
Quintuple tests
First trimester NT and sec-
ond trimester total hCG,
uE3, AFP and inhibin A
1 1110 (85) 91 (82, 96) 95 (94, 96) 5% FPR
First trimester NT and sec-
ond trimester f ree ßhCG,
uE3, AFP and inhibin A
1 1110 (85) 91 (82, 96) 95 (94, 96) 5% FPR
First
trimester NT and PAPP-A,
and second trimester f ree
ßhCG, uE3 and AFP
1 1100 (85) 92 (84, 97) 95 (94, 96) 5% FPR
1
8
F
irst
a
n
d
se
c
o
n
d
trim
e
ste
r
se
ru
m
te
sts
w
ith
a
n
d
w
ith
o
u
t
fi
rst
trim
e
ste
r
u
ltra
so
u
n
d
te
sts
fo
r
D
o
w
n
’s
sy
n
d
ro
m
e
sc
re
e
n
in
g
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
First
trimester NT and PAPP-A,
and second trimester total
hCG, uE3 and AFP
2 33,337 (171) 88 to 92 95 to 97 5% FPR, 1:200 risk
Sextuple tests
First trimester NT, PAPP-A
and f ree ßhCG, and second
trimester total hCG, uE3 and
AFP
1 5060 (13) 100 (75, 100) 97 (96, 97) 1:250 risk
Septuple tests
First trimester NT, PAPP-
A and f ree ßhCG, and sec-
ond trimester uE3, AFP, to-
tal hCG and inhibin A
1 33,546 (87) 94 (87, 98) 89 (89, 89) 1:150 risk
Contingent tests
First trimester NT, PAPP-A
and f ree ßhCG, if risk 1:30-1:
1500,second trimester total
hCG, uE3, AFP and inhibin A
1 32,355 (86) 91 (82, 96) 95 (95, 96) 1:270 risk
First trimester NT, PAPP-A
and f ree ßhCG, if risk 1:30-1:
1500, second trimester f ree
ßhCG, uE3, AFP and inhibin
A
1 7842 (59) 95 (86, 99) 95 (94, 95) 5% FPR
Stepwise tests
1
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First trimester NT and
PAPP-A, if risk < 1:100, sec-
ond trimester f ree ßhCG,
uE3 and AFP
1 1507 (12) 92 (62, 100) 97 [(96, 98) 1:250 risk
First trimester NT, PAPP-A
and f ree ßhCG, if risk < 1:30,
second trimester total hCG,
uE3, AFP and inhibin A
1 32,355 (86) 92 (84, 97) 95 (95, 95) 1:270 risk
First trimester NT, PAPP-A
and f ree ßhCG, if risk < 1:30,
second trimester f ree ßhCG,
uE3, AFP and 2T inhibin A
1 7842 (59) 97 (88, 100) 95 (94, 95) 5% FPR
*Tests evaluated by at least one study are presented in the table. Where there were two studies at the same threshold,
est imates of summary sensit ivity and summary specif icity were obtained by using univariate f ixed-ef fect logist ic regression
models to pool sensit ivit ies and specif icit ies separately. if the threshold used was a 5% FPR, then only the sensit ivit ies
were pooled. The range of sensit ivit ies and specif icit ies are presented where there were two studies and the thresholds
used were dif ferent.
AFP = alpha-fetoprotein; ßhCG = beta human chorionic gonadotrophin; FPR = false posit ive rate; hCG = human chorionic
gonadotrophin; NT = nuchal translucency; PAPP-A = pregnancy-associated plasma protein-A; uE3 = unconjugated oestriol
CI = conf idence interval
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D I S C U S S I O N
Summary of main results
We found 22 studies evaluating first and second trimester Down’s
syndrome serum screening tests, with or without first trimester
nuchal translucency (NT). Few studies provided unconfounded
comparisons of test strategies by applying and comparing several
strategies using the same serum sample, the majority of studies
only evaluating a single test combination. A summary of results
for the six most commonly evaluated test strategies is given in
Summary of findings 1, and the remaining 26 test strategies are
given in Summary of findings 2.
Three key findings were noted.
1. The combined test comprised of first trimester NT and
PAPP-A, and second trimester total hCG, uE3, AFP and Inhibin
A, and maternal age evaluated in three studies (Malone 2005;
Wald 2003b; Wald 2009) estimated a sensitivity of 95%
(confidence interval (CI) 90 to 97) at a cut-point of 5% FPR. In
indirect comparisons this test combination significantly
outperformed all others, except the test combination of first
trimester NT, first trimester PAPP-A, second trimester free
ßhCG, second trimester uE3, second trimester AFP, second
trimester Inhibin A, and maternal age with a sensitivity of 92%
(95% CI 88 to 95) for a fixed 5% FPR.
2. In direct comparisons of tests in the same population of
women, no test was found to be significantly better. These
comparisons were based on one or two studies, and are therefore
unlikely to be powered to detect differences.
3. Stepwise and contingent screening strategies show
promising detection rates for fixed FPRs, however due to the
nature of the test strategies it is not appropriate to make
comparisons between these tests and those that do not involved
stratification or risk at several different points in the screening
journey. These test strategies warrant further study.
Strengths and weaknesses of the review
This review is the first comprehensive review of first and second
trimester serum and ultrasound screening. We examined papers
from around the world, covering a wide cross-section of women
in varying populations. We contacted authors to verify data where
necessary to give as complete a picture as possible while trying to
avoid replication of data.
There were a number of factors that made meta-analysis of the
data difficult, which we tried to adapt for in order to allow for
comparability of data presented in different studies.
1. There were many different cut-points used to define
pregnancies as high or low risk for Down’s syndrome. This
means that direct comparison is more difficult than if all studies
used the same cut-point to dichotomise their populations.
2. There were many different risk equations and software
applications in use for combination of multiple markers, which
were often not described in the papers. This means that risks
may be calculated by different formulae and they may not be
directly comparable for this reason. It is possible that this is
responsible for unexplained heterogeneity in results.
3. Different laboratories and clinics run different assays and
use different machines and methods. This may influence raw
results and subsequent risk calculations. Many laboratories have
a quality assessment or audit trail, however, this may not
necessarily be standard across the board. For example, how many
assays are run, how often medians are calculated and adjusted for
a given population and how quickly samples are tested from
initially being taken.
4. Few studies made direct comparisons between tests, making
it difficult to detect if a real difference exists between tests (i.e.
how different tests perform in the same population). There were
differences in populations, with assay medians being affected, for
example, by race. It is not certain whether it is appropriate to
make comparisons between populations which are inherently
different.
5. We were unable to perform the investigations of
heterogeneity that we had originally intended to because the data
simply were not available. The vast majority of papers looking at
pregnancies conceived by IVF, affected by diabetes, multiple
gestation or a family history of Down’s syndrome involved
unaffected pregnancies only.
In addition, the search for this review was last updated in August
2011, and it is possible that new studies may have been published
which have not been included. Since the search was completed we
have kept a watching brief on outputs and are not aware of any
studies with large sample sizes which could substantially affect the
findings.
Applicability of findings to the review question
Potentially, when planning screening policy or a clinical screening
programme, clinicians and policy makers need to make decisions
about a finite number of tests or type of tests that can be offered.
These policies are often driven by both the needs of a specific pop-
ulation and by financial resources. Economic analysis was consid-
ered to be outside of the scope of this review. Many of the tests
examined as part of this review are already commercially available
and in use in the clinical setting. The studies were carried out on
populations of typical pregnant women and therefore, the results
should be considered comparable with most pregnant populations
encountered in every day clinical practice.
We were unable to extract information about harms of testing, in-
formation about miscarriage rates and uptake of definitive testing
as the data were not available the majority of the time. While it
is unlikely that major differences between the tests evaluated here
exist in terms of direct harms of testing, as they are all based on
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ultrasound, with or without a blood sample, differences in accu-
racy may lead to differences in the use of definitive testing and its
consequent adverse outcomes.
In some countries with a defined screening policy (i.e. the UK),
first trimester screening plays a major role, usually in combina-
tion with first trimester ultrasound scanning, and second trimester
serum screening is also readily available. In other countries how-
ever, theremay only be a limited range of tests ormarkers available-
often second trimester markers, rather than first trimester mark-
ers. The results of this review should be interpreted and applied in
the context of test availability and local restrictions, populations
or policies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence supports the use of the six marker maternal age-
adjusted combination of first trimester nuchal translucency (NT)
and pregnancy-associated plasma protein-A (PAPP-A) with sec-
ond trimester total human chorionic gonadotrophin (hCG), un-
conjugated oestriol (uE3), alpha-fetoprotein (AFP) and inhibin A,
which outperformed other test strategies. However the evidence
was limited, based on small numbers of studies and the finding
was not demonstrated in direct comparison of markers in the same
populations of women. We cannot recommend a single test com-
bination for Down’s syndrome screening. The choice of multiple
markers will depend on the availability of certain assays in local
laboratories. There is little evidence to recommend the use of first
and second trimester serum markers without the addition of first
trimester ultrasound. We would not recommend that these tests
be introduced into wider clinical practice without careful consid-
eration of cost.
Implications for research
Further evaluation of test combinations involving contingent and
stepwise strategies are required to determine whether they offer
superior test performance.
Future studies should ensure that adequate sample sizes are re-
cruited, and take opportunities to make comparisons of test per-
formance testing several alternative test combinations on the same
population. Such direct comparison removes issues of confound-
ing when making test comparisons, and allows a clear focus on
testing the incremental benefit of increasingly complex and expen-
sive testing strategies. The reporting of studies of test accuracy can
be improved and more closely adhere to the standards for the re-
porting of diagnostic accuracy studies (STARD) guideline. Three
key aspects of this are: 1) formally testing the statistical signifi-
cance of differences in test performance in direct comparisons and
estimating incremental changes in detection rates (together with
confidence intervals); 2) clearly reporting the number of mothers
studied and their results; and 3) reporting the numbers of women
who are lost to follow-up.Many authors reported results of extrap-
olating findings to age-standardised national cohorts to demon-
strate the performance of the test, and failed to report the actual
numbers studied and evaluated.
For the purposes of meta-analysis and to allow for comparisons
to be made between different tests and combinations, we would
recommend the publication of consensus standard algorithms for
estimating risk, and reporting of test performance at a standard set
of thresholds. This would be difficult to achieve and implement,
but an attempt at consensus should be made.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aagaard-Tillery 2009
Clinical features and settings Routine screening
Participants 7842 participants who underwent both first and second trimester screening and a second
trimester genetic sonogram
USA - The First and Second Trimester Evaluation of Risk (FASTER) trial (13 centres)
Dates not specified
Pregnant women
Mean maternal age 30.6 years (SD 6.1 years)
Singleton pregnancies
11-13 and 15-23 weeks’ gestation
Study design Prospective cohort study
Target condition and reference standard(s) Down’s syndrome: 59 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT, PAPP-A and free ßhCG (details not reported)
Second trimester AFP, uE3, free ßhCG and inhibin-A (details not reported)
Second trimester genetic sonogram
Detection rate for a 5% false positive rate and for fixed 1:270 cut-off
Follow-up Details of follow-up not reported
Aim of study To estimate the effectiveness of second trimester genetic sonography inmodifyingDown’s
syndrome screening results
Test characteristics
Reference standard used
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
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Aagaard-Tillery 2009 (Continued)
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
Yes Of 33,546 trial participants only 7842 women with complete
information for all screening tests and genetic sonography were
included in the study
Audibert 2001
Clinical features and settings Routine screening
Participants 4130 participants
France - single centre
May 1994 to December 1997
Pregnant women
Mean maternal age 30.1 years (all under 38 years)
Singleton pregnancies
12-13 weeks’ gestation
Crown rump length between 38 mm and 84 mm
Study design Prospective consecutive series study
Target condition and reference standard(s) Down’s syndrome: 12 cases
Reference standards: prenatal karyotype conducted (in 7.6% of patients) depending on
presence of risk > 1/125, high maternal age, parental anxiety, history of chromosomal
defects or parental translocation or abnormal second trimester scan
Cytogenetic testing of newborns with suspected abnormalities
Postmortum on terminations of pregnancy or miscarriages
Follow-up to neonatal examination in newborns
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Audibert 2001 (Continued)
Index and comparator tests Maternal age
First trimester NT planned at 12-13 weeks, 3 mm cut-off
Second trimester serum hCG between 14 and 17 weeks (Amerlite, Orthoclinical diag-
nostics machine)
Second trimester serum AFP between 14 and 17 weeks (Amerlite, Orthoclinical diag-
nostics machine)
Serum tests in 3790 women
Risk cut off 1:250
Follow-up Outcome assessed at delivery and postnatal paediatric examination. 35 women were lost
to follow-up and excluded from the analysis. 340 women had first trimester NT but not
second trimester serum testing
Aim of study To compare first trimester NT and second trimester maternal serum measurements as
alternative methods of antenatal screening in a low risk population and to evaluate the
consequence of combining the results in the estimation of risk
Test characteristics
Reference standard used
Notes Women lost to follow-up were excluded in the final analysis. All detected cases resulted
in termination
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
58First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Audibert 2001 (Continued)
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes NT was not measured or not recorded in 219 women and these
patients were excluded from the study
Withdrawals explained?
All tests
Yes 35 women were lost to follow-up (they had all had normal NT
results). 340 women who did not want second trimester serum
screening withdrew from that part of the study
Babbur 2005
Clinical features and settings Women requesting screening (self-paying service) and women attending on account of
previous pregnancy history of fetal abnormality
Participants 3,188 participants
UK - Maternity Hospital
August 2001 - March 2004
Pregnant women
Singleton pregnancies
Median maternal age 37 years (range 19-46 years)
11-14 weeks’ gestation
45 mm to 84 mm crown rump length
Viable fetus
Study design Prospective cohort study
Target condition and reference standard(s) Down’s syndrome: 25 cases
Reference standards: Invasive testing offered to women with NT > 3 mm or risk > 1:
250 as defined by combined NT and serum results (CVS from 11 weeks, amniocentesis
from 15 weeks). Rapid in situ hybridisation test in patients with risk > 1:30. No details
given of any follow-up to birth
Index and comparator tests First trimester NT in all women (FMF methods)
Second trimester serum uE3, AFP and hCG (AutoDELFIA(TM) time-resolved fluo-
roimmunoassay (Perkin Elmer)) at 14 weeks. Offered to patients with negative first
trimester NT (n = 2725, 85% accepted)
Follow-up Details of follow-up not reported
Aim of study To determine the detection and false positive rates for trisomy 21 using 2-stage combined
NT and triple testing whilst disclosing abnormal NT measurements at the scan
Test characteristics
Reference standard used
Notes Women with miscarriages excluded
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Babbur 2005 (Continued)
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high riskwomen as done
in practice
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference
standard
Differential verification avoided?
All tests
No Choice of reference standard depended on
index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the
index test
Reference standard results blinded?
All tests
No Reference standard interpreted with
knowledge of index test results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge
of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements
Withdrawals explained?
All tests
Yes 463 patients having NT did not go on to
have second trimester serum testing
Baviera 2010
Clinical features and settings Routine screening
Participants 579 participants: 17 cases and 562 controls matched for gestational age
Italy - single centre
December 2006 - May 2009
Pregnant women
Mean maternal age 35.3 years (cases) and 30.4 years (controls)
Singleton pregnancies
7-10 and 14-17 weeks’ gestation
Study design Case-control study
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Baviera 2010 (Continued)
Target condition and reference standard(s) Down’s syndrome: 17 cases (14 identified by amniocentesis, 3 from follow-up to birth)
Reference standard: amniocentesis or follow-up to birth
Index and comparator tests Frozen serum samples tested for:
First trimester and second trimester ADAM12s (time resolvedfluorescence immunoassay,
DELFIA assay kit, Perkin Elmer Life and Analytical Sciences)
First trimester PAPP-A (details not reported)
Second trimester AFP, uE3 and hCG (details not reported)
Follow-up Details of follow-up not reported
Aim of study To demonstrate the potential value of repeated measures of ADAM12s for the screening
of Down’s syndrome
Test characteristics
Reference standard used
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
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Baviera 2010 (Continued)
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Benattar 1999
Clinical features and settings Routine screening
Participants 1656 participants
France - single centre
January to December 1995
Pregnant women
Singleton pregnancies
Mean maternal age 32 years (range 16-46 years)
Enrolled before 13 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 5 cases
Reference standards: amniocentesis due to maternal age > 38 years (6.1% or women)
. Karyotyping encouraged for women with positive result on 1 or more index test. No
details of reference standard for index test negative women
Index and comparator tests Maternal age
NT at 12-14 weeks (Toshiba SSA 270), cut-point 1:250
First trimester (12-14 weeks) serum AFP and free ßhCG (Elsa AFP and Elsa free BhCG;
Cis-Bio International)
Second trimester (15-18 weeks) serum AFP and total hCG (AFP-2T and hCG-60;
Ortho-Clinical Diagnostics)
All women had NT and serum testing
Follow-up Details of follow-up not reported. 12 patients were lost to follow-up due to miscarriages
Aim of study To evaluate the sequential combination of ultrasound screening for fetal aneuploidy at
11-14 weeks with maternal biochemistry at 12-14 and 15-18 weeks of gestation
Test characteristics
Reference standard used
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
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Benattar 1999 (Continued)
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Bestwick 2010
Clinical features and settings Routine screening
Participants 22,746 participants
UK - 2 clinics
January 2003 - December 2008
Pregnant women
Median maternal age 39 years (Down’s syndrome) and 34 years (non-Down’s syndrome)
11-13 and 14-22 weeks’ gestation
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 106 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT, PAPP-A and free ßhCG (details not reported)
Second trimester AFP, uE3, free ßhCG and inhibin-A (details not reported)
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Bestwick 2010 (Continued)
Follow-up Data obtained from the Hospitals, the regional cytogenetic unit and the National Down
Syndrome Cytogenetic Register
Aim of study To determine whether the SD of NT measurements has decreased over time and, if so,
to revise the estimate and assess the effect of revising the estimate of the SD on the
performance of antenatal screening for Down’s syndrome
Test characteristics
Reference standard used
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
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Cuckle 2008
Clinical features and settings Routine screening
Participants 36,740 participants undergoing first trimester screening (32,355 also underwent second
trimester screening)
USA - 15 centres, FASTER trial
Pregnant women
Singleton pregnancies
Maternal age not reported
11-13 and 15-18 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 116 cases (86 cases had both first trimester and second trimester
screening)
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT, PAPP-A and free ßhCG (details not reported)
Second trimester AFP, total hCG, uE3 and inhibin-A (details not reported)
Follow-up Details of follow-up not reported
Aim of study To compare the contingent, step-wise and integrated screening policies
Test characteristics
Reference standard used
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
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Cuckle 2008 (Continued)
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Goh 1996
Clinical features and settings Routine screening
Participants 11,964 participants
Singapore - University Hospital
1989 to 1992
Pregnant women
Singleton pregnancies
Median maternal age 35 years (mean 33 years)
12-22 weeks’ gestation
Study design Cohort
Target condition and reference standard(s) Down’s syndrome: 34 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester and second trimester AFP and hCG (EIA method, kits from Abbot Lab-
oratory, USA) and uE3 (In-house indirect, extraction radioimmunoassay)
Risk cut-points of 1:250 and 1:384
Follow-up No details of methods of follow-up
Aim of study To appraise the potential effectiveness of implementing a prenatal screening programme
on a local population in Singapore
Test characteristics
Reference standard used
Notes
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Goh 1996 (Continued)
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Guanciali-Franchi 2010
Clinical features and settings Routine screening
Participants 5060 participants
Italy - Genetic unit
January 2006 - April 2009
Pregnant women
Mean maternal age 31.8 years
Singleton pregnancies
10-12 and 15-17 weeks’ gestation
Study design Prospective cohort
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Guanciali-Franchi 2010 (Continued)
Target condition and reference standard(s) Down’s syndrome: 13 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (by certified sonographers)
First trimester PAPP-A and free ßhCG (details not reported)
Second trimester AFP, hCG and uE3 (details not reported)
Cross-trimester test: all first trimester and second trimester tests
Cut-point 1:250
Follow-up Stated that follow-up until delivery was available for all women
Aim of study To evaluate the effectiveness of cross-trimester testing in selecting high risk pregnant
women to undergo invasive prenatal diagnosis
Test characteristics
Reference standard used
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
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Guanciali-Franchi 2010 (Continued)
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Habayeb 2010
Clinical features and settings Routine screening
Participants 1507 participants
UK - Fetal medicine unit
September 2007 - December 2008
Pregnant women
Median maternal age 35.4 years (range 18-49 years)
9-10, 11-13 and > 14 weeks’ gestation
Study design Cohort
Target condition and reference standard(s) Down’s syndrome: 12 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
Early first trimester PAPP-A (9weeks’ gestation) (AutoDELFIAPAPP-Akit, PerkinElmer
LAS (UK) Ltd)
First trimester NT (11-13 weeks’ gestation) (General Electric E8, Voluson 730 Pro, GE
Healthcare)
Second trimester AFP, free ßhCGand uE3 (at or after 14weeks’ gestation) (AutoDELFIA
(TM) time-resolved fluoroimmunoassay, PerkinElmer Life Sciences)
Second trimester tests given if first trimester risk low (< 1:100) or invasive testing declined
Cut-point for second-stage risk 1:250
Follow-up Data recorded on a fetal medicine database and combined with data held on separate
databases for pregnancy outcome and the regional cytogenetic laboratory. Cytogenetic
test results available for all women delivering in the region
Aim of study To audit a model combining early PAPP-A with NT and early triple test
Test characteristics
Reference standard used
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
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Habayeb 2010 (Continued)
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Herman 2002
Clinical features and settings Routine screening
Participants 531 participants: 23 cases and 508 consecutive controls
Israel - Medical centre
Pregnant women
10-14 and 16-19 weeks’ gestation
Study design Case-control
Target condition and reference standard(s) Down’s syndrome: 23 cases
Reference standard: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT ()
Second trimester AFP, hCG and uE3 ()
70First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Herman 2002 (Continued)
Follow-up Some cases obtained through follow-up to birth. No details of follow-up in controls
reported
Aim of study To compare the results of the disclosure and non-disclosure approaches, using the clinical
data of first trimester ultrasound and second trimester serum screening tests among the
same groups of normal and trisomy 21-affected pregnancies
Test characteristics
Reference standard used
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
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Lam 2002
Clinical features and settings Routine screening
Participants 16,237 participants undergoing NT and biochemical testing
Hong Kong - multi-centre study
1997 to 2000
Pregnant women
Mean maternal age 30.5 years (19% > 35 years)
10-14 weeks and 15-18 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 35 cases
Reference standards: women considered high risk offered CVS (0.7%) or amniocentesis
(11.8%). Follow-up to birth
Index and comparator tests Maternal age
First trimester NT (FMF methods)
Second trimester free ßhCG and AFP (methods not reported)
Follow-up By review of hospital and laboratory records and by directly telephoning women. Partic-
ipants who defaulted the second trimester serum tests (n = 1015) and those who miscar-
ried after NT but before serum testing (n = 91) were excluded from the study. Outcome
obtained in 15,253 patients (93.9%)
Aim of study To report data on participants undergoing both first and second trimester methods of
screening to assess the relative efficacy of different methods of screening
Test characteristics
Reference standard used
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
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Lam 2002 (Continued)
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes NT successful in 99.8% of cases
Withdrawals explained?
All tests
Yes Details given for patients excluded and those without follow-up
data
Malone 2005
Clinical features and settings Routine screening
Participants 38,033 participants
USA - multi-centre study (15 centres)
October 1999 to December 2002
Pregnant women
21.6% of women aged ≥ 35 years
Singleton pregnancies
Live fetuses
10-13 and 15-18 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 92 cases (87 had first trimester and second trimester screening)
Reference standards: amniocentesis (offered to women with positive results from any
screening test) or follow-up to birth
Index and comparator tests Maternal age
First trimester NT in 36,306 patients (92.9%)
First trimester PAPP-A and free ßhCG in 37,843 patients (99.5%)
Second trimester AFP, total hGC, uE3 and inhibin-A in 35,236 patients (92.6%)
All tests done in 33,546 patients (88.2%)
Follow-up Follow-up with computerised tracking system. Medical records were reviewed in cases of
1) possible medical problem suspected 2) positive screening test results with no karyotype
data, 3) 10% random sample of all enrolled patients. Follow-up to birth complete in 36,
378 patients (97%)
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Malone 2005 (Continued)
Aim of study To evaluate first trimester and/or second trimester screening tools for Down’s syndrome
Test characteristics
Reference standard used
Notes Unclear which types of patients did not have follow-up data. Appears that aborted/
miscarried fetuses did not have follow-up (note in table)
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
No Not all women received a reference standard (3% had no as-
certainment of pregnancy outcome, patients not excluded from
study)
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes NT failed or rejected at review in 7.1% or women
Withdrawals explained?
All tests
Yes Details given for patients who did not undergo different index
tests
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Okun 2008 Integrated
Clinical features and settings Routine screening
Participants 32,227 participants undergoing integrated screening (a separate cohort evaluated for first
trimester screening)
January 2003 - December 2005
Canada - 2 hospitals
Pregnant women
Mean maternal age 32 years
11-14 and 15-18 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 86 affected cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (most sonographers had FMF certification)
First trimester free ßhCG and PAPP-A (DSX Four Plate Automated ELISA Processing
system,DynexTechnologies andDPCImmulite 2000 automated immunoassay analyser,
Siemens Medical Solutions Diagnostics)
Second trimester hCG, AFP and uE3 (Time-resolved fluoroimmunoassay, PerkinElmer
AutoDelfia)
Risk cut-point 1:200 or NT ≥ 3.5 mm
Results presented with and without adjustment for bias due to miscarriages (viability
bias)
Follow-up From cytogenetics databases in both Hospitals, the Canadian Institute for Health Infor-
mation, labour and delivery databases, written and phone follow-up with care providers
and phone follow-up with women after birth
Aim of study To evaluate the performance of integrated prenatal screening and first trimester combined
screening for trisomy 21 in a large Canadian urban centre
Test characteristics
Reference standard used
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
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Okun 2008 Integrated (Continued)
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
Yes 2614 (8%) of women undergoing integrated screening did not
return for the second trimester part of the test
Palomaki 2006
Clinical features and settings Routine screening
Participants 540 participants: 32 cases and 508 controls selected from same time period (within 1
month)
New York - General Hospital
Singleton pregnancies
Pregnant women
Mean maternal age cases 33.9 years (SD 4.4 years) and controls 35.9 years (SD 3.6 years)
10-13 and 14-20 weeks’ gestation
Study design Case-control study
Target condition and reference standard(s) Down’s syndrome: 32 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
Fresh samples tested for first trimester PAPP-A and Second trimester AFP, uE3 and hCG
(PerkinElmer Life and Analytical Sciences, Woodbridge, Ontario, Canada)
Frozen samples thawed and tested for second trimester inhibin-A (Diagnostic Systems
Laboratories, Webster, TX) and PAPP-A (PerkinElmer)
Cut-points of 1:100, 1:150, 1:200 and 1:250
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Palomaki 2006 (Continued)
Follow-up Outcome of pregnancy available from the Ontario Multiple Marker Screening Database
Aim of study To confirm that measuring pregnancy-associated plasma protein-A in both first and
second trimester serum samples improves Down’s syndrome screening
Test characteristics
Reference standard used
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes 2 cases and 6 controls had insufficient sample to measure second
trimester inhibin-A and were removed from the analysis
Withdrawals explained?
All tests
No No details of withdrawals given
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Rodrigues 2009
Clinical features and settings Routine screening
Participants 3299 participants: 2290 undergoing integrated and 1009 undergoing serum integrated
screening
Portugal - screening programme
March 2003 - August 2007
Pregnant women
Median maternal age: integrated screening 30.6 years, serum integrated screening 30.9
years
First and second trimester
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 14 cases (integrated screening 8, serum integrated screening 6)
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (details not reported)
First trimester PAPP-A and second trimester free ßhCG and AFP (TRACE technology,
Brahms Kryptor Systems)
Risk cut-point 1:300 for integrated and serum integrated screening
Follow-up Detail of follow-up not reported
Aim of study To report an audit of an integrated and serum integrated screening programme
Test characteristics
Reference standard used
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
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Rodrigues 2009 (Continued)
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Rozenberg 2002
Clinical features and settings Routine screening
Participants 9118 participants
France - 2 tertiary and 4 primary referral centres
March 1994 - December 1997
Pregnant women
Median age 30.5 years (18-37 years)
Singleton pregnancies
12-14 and 14-17 weeks’ gestation
Study design Prospective cohort
Target condition and reference standard(s) Down’s syndrome: 21 cases
Reference standards: amniocentesis offered to patients withNT > 3mm or serummarker
risk was >1:250. Follow-up to birth
Index and comparator tests Maternal age
First trimester NT in 98.6% of women (FMF methods)
Second trimester free ßhCG (beta hCG ELISA immunoradiometric assay) and AFP
(AFP ELISA immunoradiometric assay) in 91.1% of women
Both NT and biochemical testing in 60.4% of women
Follow-up Details of follow-up not reported. 3.4% of patients were lost to follow-up and were
excluded from the study. This included 113 women (1.2%) with miscarriages
Aim of study To assess the performance of combined first trimester sonographic screening and second
trimester serum screening
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Rozenberg 2002 (Continued)
Test characteristics
Reference standard used
Notes Includes cost effectiveness analysis
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes NT was not able to be measured in 93 women (1.5%)
Withdrawals explained?
All tests
No No details of withdrawals given
Schuchter 2001
Clinical features and settings Routine screening
Participants 9342 participants
Austria - single institution
January 1994 to December 1998
Pregnant women
Mean maternal age 28 years (range 15-46 years), 10.7% ≥ 35 years
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Schuchter 2001 (Continued)
10-13 weeks’ gestation
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 19 cases
Reference standards: CVS (offered to patients with first trimester NT > 3.5 mm), amnio-
centesis (offered to patients with first trimester NT 2.5-3.4, high risk on second trimester
serum testing (> 1:250) and those > 35 years) or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (all women) (5-MHz transducer, Acuson Corp)
Second trimester AFP, E2 and hGC (triple test) offered to patients not undergoing first
trimester invasive testing (99.7% of women) (AMERLEX-M 2nd Trimester kits, Ortho
Clinical Diagnostics)
Follow-up Patients included in study if they were delivered in the same hospital where they were
screened. It is stated that all newbornswere examined formalformations by a paediatrician
after delivery
Aim of study To evaluate screening for trisomy 21 in a low risk population utilising a combination of
NT measurement in the first trimester and the triple test in the second trimester
Test characteristics
Reference standard used
Notes Women having miscarriages were excluded from the study
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
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Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No Details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Wald 2003b
Clinical features and settings Routine screening
Participants 606 participants: 101 cases, 505 controls matched for gestation, duration of storage and
centre
UK and Austria - multi-centre trial
September 1996 to April 2000
Pregnant women
9-13 and 14-20 weeks’ gestation
Study design Case-control study
Target condition and reference standard(s) Down’s syndrome: 101 cases
Rerence standards: invasive testing (following second trimester screening) or follow-up
to birth
Index and comparator tests First trimesterNT (midsagittal section, optimal magnification of thickness of translucent
space between inner skin surface and fascia covering cervical spine (white black interface
(outer) - black white interface (inner), 41 models of ultrasound machine, 20 minutes
allotted scanning time)
First trimester and second trimester serum AFP, hCG, UE3, PAPPA, free ßhCG (time
resolved fluoroimmunoassay, AutoDELFIA)
First trimester and second trimester inhibin A (Sandwich enzyme linked immunosorbent
assay, Oxford Bioinnovation)
First trimester and second trimester urinary beta core fragment, total-hCG, ITA and free
ßhCG (ITA and beta core fragment, Quest diagnostics USA)
Follow-up Follow-up by: 1) Staff at local hospitals completed a study outcome form at, or just
after. delivery, 2) Study records of CVS, amniocentesis or karyotype at birth linked to
information from cytogenic laboratories, 3) Study records linked to records of cases
of Down’s syndrome from the National Down’s Syndrome Cytogenetic Register, 4)
Information obtained from local obstetrical outcome records, 5) Forms sent to all women
with a request to return details of the outcome of their pregnancy, 6) Individual searches
in respect of women whose outcomes of pregnancy had not been obtained by any of the
previous methods. 96% Birth/Karyotype full outcome documentation obtained
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Aim of study To identify the most effective, safe and cost effective strategy for antenatal screening for
Down’s syndrome using NT, maternal serum and urine markers in the first and second
trimesters of pregnancy and maternal age in various combinations
Test characteristics
Reference standard used
Notes Performance of screening assessed at 17 weeks’ gestation. Study tried to be non-interven-
tional in the first trimester - second trimester testing was aimed to be used as the basis
for any referral for invasive testing
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear 4% of total patient cohort did not have a documented outcome
of pregnancy. Unclear if any of these included in nested case-
control study
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
Yes Rates of NT failure on average 9%. Pre-10 weeks’ gestation, >
33% failure rate, declined to 7% at 12 weeks
Withdrawals explained?
All tests
No No details of withdrawals given
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Clinical features and settings Routine screening
Participants 14,296 participants in whom screening for all markers were measured
UK - 2 Hospitals
2003 - 2007 (2004 - 2007 for 1 hospital)
Pregnant women
Singleton pregnancies
Median maternal age 33 years (range 15-51 years), 20% ≥ 37 years
10-13 and 14-22 weeks’ gestation
Study design Retrospective cohort
Target condition and reference standard(s) Down’s syndrome: 47 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (details not reported)
First trimester PAPP-A (details not reported)
Second trimester AFP, uE3, hCG, free ßhCG and, at one hospital, inhibin-A (details not
reported)
Integrated test (at 1 of the hospitals women were given the option of having only the
combined test and earlier test results)
Cut-point 1:150
Follow-up Down’s syndrome pregnancies, including those missed by screening, were ascertained
from hospital records, cytogenetic laboratories and by linking data with the National
Down Syndrome Cytogenetics Register
Aim of study To present a medical audit of screening using the Integrated test at 2 hospitals
Test characteristics
Reference standard used
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard
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Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
Wright 2010 FASTER trial
Clinical features and settings Routine screening
Participants 468 participants: 78 cases and 390 controls matched for gestational and maternal age,
ethnicity and storage duration
The First and Second Trimester Evaluation of Risk (FaSTER) dataset
USA - 15 screening centres
October 1999 - December 2002
Pregnant women
Singleton pregnancies
11-13 and 15-18 weeks’ gestation
Study design Case-control study
Target condition and reference standard(s) Down’s syndrome: 78 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
First trimester NT (details not reported)
Fresh samples tested for:
First trimester PAPP-A (details not reported)
Second trimester AFP, uE3, hCG and inhibin A (details not reported)
Frozen serum samples tested for:
First trimester hCG and uE3 (details not reported)
Second trimester PAPP-A (details not reported)
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Frozen samples tested blind to other results and pregnancy outcome
Follow-up Details not reported
Aim of study To provide estimates and confidence intervals for the performance (detection and false
positive rates) of screening for Down’s syndrome using repeatedmeasures of biochemical
markers from first and second trimester maternal serum samples taken from the same
woman
Test characteristics
Reference standard used
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
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Clinical features and settings Routine screening
Participants 239 participants: 43 cases and 196 controls (35 cases and 173 controls with second
trimester testing) matched for maternal and gestational age and sample date
USA - The North York General Hospital dataset
December 1999 - November 2007
Pregnant women
Singleton pregnancies
11-13 and 14-20 weeks’ gestation
Study design Case-control study
Target condition and reference standard(s) Down’s syndrome: 43 cases
Reference standards: karyotyping or follow-up to birth
Index and comparator tests Maternal age
Fresh samples tested for:
First trimester PAPP-A (PerkinElmer)
Second trimester AFP, uE3, and hCG (PerkinElmer)
Frozen serum samples tested for:
First trimester hCG and uE3 (details not reported)
Second trimester PAPP-A (details not reported)
Frozen samples tested blind to other results and pregnancy outcome
Follow-up Details not reported
Aim of study To provide estimates and confidence intervals for the performance (detection and false
positive rates) of screening for Down’s syndrome using repeatedmeasures of biochemical
markers from first and second trimester maternal serum samples taken from the same
woman
Test characteristics
Reference standard used
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth
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Partial verification avoided?
All tests
Yes All women received a reference standard
Differential verification avoided?
All tests
No Choice of reference standard depended on index test results
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Yes Index test interpreted without knowledge of reference standard
results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninterpretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given
AFP: alpha-fetoprotein
ß hCG: beta human chorionic gonadotrophin
CVS: chorionic villus sampling
ELISA: enzyme-linked immunosorbent assay
hCG: human chorionic gonadotrophin
NT: nuchal translucency
PAPP-A: pregnancy-associated plasma protein-A
SD: standard deviation
uE3: unconjugated oestriol
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aagaard-Tillery 2010 Results presented in another study
Abbas 1995 Unable to extract useful data
Abdul-Hamid 2004 No Down’s syndrome pregnancies
Abraha 1999 Unable to extract useful data
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Abu-Rustum 2010 Not Down’s syndrome specific
Achiron 2010 Study only includes cases of Down’s syndrome
Adekunle 1999 Unable to extract useful information
Aitken 1993 Unable to extract useful data
Aitken 1996 Fewer than 80% of pregnancies had gestational age confirmed by USS
Aitken 1996a Fewer than 80% of pregnancies had gestational age confirmed by USS
Ajayi 2011 No diagnostic data
Akbas 2001 Less than 5 Down’s syndrome pregnancies
Alexioy 2009 Study only includes test positives
Allingham-Hawkins 2011 Quantitative fluorescent polymerase chain reaction study
American College 2009 Discussion article
Antona 1998 Likely fewer than 80% of pregnancies dated by USS
Antsaklis 1999 Women screened at greater than 24 weeks’ gestation
Anuwutnavin 2009 Second trimester ultrasound
Ashwood 1987 Unable to extract useful data
Asrani 2005 Review article
Audibert 2001b Unable to ascertain whether part of screening population in Rozenberg et al. No response from authors
therefore excluded to reduce risk of data replication
Axt-Fleidner 2006 Unable to extract useful data
Azuma 2002 Unable to extract useful data
Baghagho 2004 Unable to obtain paper
Bahado-Singh 1995 USS markers greater than 14 weeks’ gestation
Bahado-Singh 1996 USS markers greater than 14 weeks’ gestation
Bahado-Singh 1999 USS markers greater than 14 weeks’ gestation
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Bahado-Singh 2002 USS markers greater than 14 weeks’ gestation
Bahado-Singh 2003 Review article
Ball 2007 Data from the FASTER trial
Bar-Hava 2001 No Down’s pregnancies in study population
Barkai 1996 No Down’s pregnancies in study population
Barnabei 1995 No Down’s pregnancies in study population
Bartels 1988 Unable to extract useful data
Bartels 1993 No Down’s pregnancies in study population
Barth 1991 Second trimester ultrasound study
Bas-Budecka 2007 No diagnostic data
Baviera 2004 Unclear method of confirmation of gestational age
Bazzett 1998 Male versus female fetuses
Beke 2008 Results are not specific to Down’s syndrome
Bellver 2005 No Down’s syndrome pregnancies in study
Benn 1995 Less than 80% follow-up
Benn 1996 Less than 80% follow-up
Benn 1997 No Down’s pregnancies in study population
Benn 1998 Less than 80% follow-up
Benn 2001 Statistical modelling (computer simulation)
Benn 2002 Modelled data
Benn 2003 Less than 80% of pregnancies dated by USS
Benn 2003a Editorial
Benn 2005 No Down’s pregnancies included
Benn 2005a Mathematical model
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Benn 2007 No follow-up information
Berry 1995 Less than 80% of pregnancies USS dated
Berry 1997 Less than 80% of pregnancies USS dated
Bersinger 1994 Gestational age not USS estimated
Bersinger 2000 Unable to extract useful data
Bersinger 2001 No Down’s syndrome pregnancies in study population
Bersinger 2003 Unable to extract useful data
Bersinger 2004 No Down’s syndrome pregnancies in study population
Bersinger 2005 No Down’s syndrome pregnancies in study population
Bestwick 2008 All healthy pregnancies
Biggio 2004 Cost-effectiveness analysis
Bilardo 2011 Not a proper sample - most had elevated NT
Bindra 2002 Review article
Blundell 1999 Unable to extract useful data
Boormans 2010 Study of testing on amniocentesis samples
Boots 1989 Population risk factor calculations
Bornstein 2009a No diagnostic data
Bornstein 2009b No diagnostic data
Bornstein 2010 No diagnostic data
Borowski 2007 No diagnostic data
Borrell 2007 No follow-up data
Borrell 2009 Based on SURUSS (Serum, Urine and Ultrasound Screening Study) data - second trimester serum
parameters not actually measured
Borruto 2002 Unable to extract useful data
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Bottalico 2009 Second trimester ultrasound
Boue 1990 Review article
Bradley 1994 Screen negative population gestations not confirmed by ultrasound
Braithwaite 1996 Review article
Brambati 1995 USS screening inclusive of women greater than 14 weeks’ gestation
Brambati 1996 Review article
Brizot 1995 Unable to extract useful data
Brizot 1995a Unable to extract useful data
Brizzi 1989a Second trimester ultrasound
Brock 1990 Unable to extract useful data
Calda 2010 No data for false positive rates
Campogrande 2001 Unable to extract useful data
Canick 1988 Unable to extract useful data
Canick 1995 Unable to extract useful data
Canini 2002 No Down’s syndrome pregnancies in study population
Cans 1998 Second trimester ultrasound
Carreras 1991 Second trimester ultrasound
Caughey 2007 No diagnostic data
Cebesoy 2008 No diagnostic data
Chelli 2008 No follow-up for false negatives
Chen 1999 Review article
Chen 2002 No Down’s syndrome pregnancies in study population
Chen 2004 Less than 5 Down’s cases in study population
Chen 2005 Unable to extract useful data
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Chen 2008 No diagnostic data
Cheng 1993 Likely that fewer than 80% of gestational age confirmed by USS
Cheng 1999 Case series
No Down’s syndrome pregnancies in study population
Cheng 2004a No Down’s syndrome pregnancies in study population
Cheng 2004b No Down’s syndrome pregnancies in study population
Chitayat 2002 Less than 5 Down’s cases in study population
Chiu 2011 Study of maternal DNA testing
Cho 2009 Study of testing amniotic fluid
Chou 2009 Not possible to calculate specificity
Christiansen 2002 Unable to extract useful data
Christiansen 2007 Unable to extract useful data
Christiansen 2008 No diagnostic data
Chung 2000 Less than 5 Down’s syndrome pregnancies in study population
CNGOF 1996 Unable to obtain translation
Cocciolone 2008 Unable to extract useful data - attempted to contact author
Cole 1996 Review article
Comas 2001 USS at greater than 14 weeks
Comas 2002a USS at greater than 14 weeks
Comas 2002b USS at greater than 14 weeks
Comstock 2006 Unable to extract useful data
Conde 1998 Review article
Cowans 2011 No diagnostic data
Crossley 1991 Less than 80% of pregnancies had gestational age confirmation by ultrasound
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Crossley 1993 Less than 80% of pregnancies had gestational age confirmation by ultrasound
Crossley 1996 No Down’s syndrome pregnancies in study population
Crossley 2002 Adjustment factors for smokers
Cuckle 1984b Gestational age not confirmed by USS
Cuckle 1987a Gestational age not confirmed by USS
Cuckle 1987b No gestational age limits given
Cuckle 1990 Paper presenting adjustment factors
Cuckle 1996a Data modelled on 4 meta-analysed studies
Cuckle 1999b Unable to extract useful data
Cuckle 1999c Review article
Cullen 1990 Abnormal scans only in study population
Cusick 2004 Less than 5 Down’s syndrome pregnancies in study population
Cusick 2007 ST ultrasound
Dancoine 2001 No Down’s syndrome pregnancies in study population
Dane 2008 Not specific to Down’s syndrome
De Biasio 2000 Unable to extract useful information
De Biasio, 1999 Unable to ascertain whether overlapping populations between several papers - attempted to contact
author with no response
De Biasio, 2001 Unable to ascertain whether overlapping populations between several papers - attempted to contact
author with no response
De Graaf 1991 Unable to extract useful data
De Graaf 1999 Modelled data
Del Carmen Saucedo 2009 No follow-up information
DeVore 2001 Second trimester ultrasound
Dhaifalah 2007a Unable to obtain translation
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Dhaifalah 2007b Unable to obtain translation
Dhallan 2007 DNA testing of blood samples from parents
Dickerson 1994 Comment
Dimaio 1987 Gestational age by USS only in screen positive population
Doran 1986 Ultrasound confirmation of gestational age performed in screen positive women only
Dreux 2008 No information for specificity
Drugan 1996a Second trimester ultrasound
Drugan 1996b Unable to extract useful data
Drysdale 2002 Fewer than 5 Down’s syndrome pregnancies in population
Dugoff 2008 Not specific to Down’s syndrome
Ebell 1999 Review article
Economides 1998 Unable to extract useful data
Erickson 2004 No Down’s syndrome pregnancies in population
Evans 1996 No Down’s syndrome pregnancies in population
Evans 2007 Data previously presented in another study
Falcon 2005 Unable to extract useful data
Falcon 2006 Unable to extract useful data
Ford 1998 Audit
Frishman 1997 No Down’s syndrome pregnancies in population
Fukada 2000 Unable to extract useful data
Gaudry 2009 Study of karyotyping
Gebb 2009 Study only examines screen positives
Geerts 2008 Study only examines abnormal foetuses
Geipel 2010 ST ultrasound
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Gekas 2009 Diagnostic data from other studies
Gekas 2011a Diagnostic data from other studies
Gekas 2011b Diagnostic parameters from other studies
Gerovassili 2007 No diagnostic data
Ghidini 1998 Comparison of male versus female fetuses
Goetzinger 2010 Second trimester ultrasound
Goldie 1995 Fewer than 80% of study population and gestational age confirmed by USS
Gollo 2008 Only 1 case of Down’s syndrome
Gonçalves 2004 Greater than 14 weeks USS screening
Goodburn 1994 Likely that fewer than 80% of pregnancies had gestational age estimated by USS
Gorduza 2007 Study of FISH technique
Grace 2010 ST ultrasound
Grati 2010 No diagnostic data
Gray 2009 ST ultrasound
Gregor 2007 Unable to obtain translation
Gregor 2009 Unable to obtain translation
Grether 2009 Systematic review and guidelines
Grozdea 2002 Unable to extract useful data
Guo 2010 Study of fetal samples
Gyselaers 2004a Less than 80% follow-up
Gyselaers 2004b Less than 80% follow-up
Gyselaers 2006a Unaffected pregnancies only
Gyselaers 2006b Unable to extract useful data
Hackshaw 1995 No Down’s syndrome pregnancies in population
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Hackshaw 2001 No Down’s syndrome pregnancies in population
Haddow 1992 Less than 80% of pregnancies had gestational age confirmed by ultrasound scan
Hadzsiev 2007 Study of FISH technique
Hafner 1995 Less than 5 Down’s pregnancies in study population
Hallahan 1998 Gestational age greater than 24 weeks
Han 2008 Study of findings on amniocentesis
Harper 2010 Second trimester ultrasound
Harrison 2006 Less than 80% of pregnancies had gestational age confirmed by ultrasound scan
Harry 2006 Editorial
Hayashi 1995 Unable to extract useful data
Hayashi 1996 Less than 5 Down’s pregnancies in study population
Heikkila 1997 Fewer than 80% of pregnancies had gestational age confirmed by USS
Heinig 2007 No Down’s syndrome data
Heinonen 1996 No Down’s syndrome pregnancies in population
Herman 2000 No Down’s syndrome pregnancies in study population
Herman 2003 Correlation between markers, not evaluation of screening tests
Herrou 1992 Unable to extract useful data
Hershey 1985 Gestation unclear
Hershey 1986 Gestation based on LMP
Hewitt 1993 Unable to extract useful data
Hills 2010 Study of testing on CVS and amniocentesis samples
Ho 2010 Study of FISH diagnosis
Hogdall 1992 Unclear method of determination of gestational age
Unable to extract useful data
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Hong Kong Practitioner CME
Hoogendoorn 2008 Diagnostic data from other studies used
Howe 2000 Second trimester ultrasound scans
Hsiao 1991 Unable to obtain translation
Hsieh 1999 No Down’s syndrome pregnancies in study population
Hsu 1997a Adjustment factors
Hsu 1998a No Down’s syndrome pregnancies in study population
Hsu 1999b No Down’s pregnancies
Hu 2007 Same data as Liu 2010
Huang 2003 No Down’s syndrome pregnancies in study population
Huang 2007a Not possible to obtain detection rate
Huang 2007b No diagnostic data
Huggon 2004 Study of cardiac function in pregnancies with normal and abnormal NT results
Hui 2003 No Down’s syndrome pregnancies in population
Hui 2005 No Down’s syndrome pregnancies in population
Hultén 2004 Editorial/commentary
Hung 2003 Modelling
Hung 2008 Second trimester ultrasound
Hurley 1993 Unable to extract useful data
Huttly 2004 No Down’s syndrome pregnancies in population
Hwa 2004 Less than 5 Down’s pregnancies in population
Iles 1996 Review
Ind 1994 Unable to extract useful data
Ivorra-Deleuze 2010 No diagnostic data
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Jakobsen 2011 Not Down’s syndrome specific
Jean-Pierre 2005 Review article
Johnson 1991 Gestatiojnal age estimated by USS in fewer than 80% of cases
Johnson 1993 Normal pregnancies only
Jorgensen 1999 Gestation greater than 14 weeks for USS
Jorgez 2007 Study of DNA testing on maternal blood
Josefsson 1998 No Down’s syndrome pregnancies in study population
Jou 2001 Less than 5 Down’s syndrome pregnancies in study population
Jun-Tao 2003 Unable to obtain translation
Jung 2007 ST ultrasound
Kagan 2006 Screen positive pregnancies only
Kagan 2007 No diagnostic data
Kagan 2008 Not Down’s syndrome detection
Kalelioglu 2007 ST ultrasound
Kautzmann 1995 Fewer than 80% pregnancies had gestational age estimated by USS
Kazerouni 2009 Not possible to obtain complete diagnostic data
Keith 1992 Summary article
Kelekci 2004 Less than 5 Down’s syndrome pregnancies in population
Kellner 1995a Less than 5 Down’s syndrome pregnancies in population
Kellner 1995b Less than 80% follow-up
Unable to ascertain proportion of population with gestational age confirmed by USS
Kellner 1997 Assumption of normal karyotype without reference standard in significant proportion of control
pregnancies
Kirkegaard 2008 FPR only calculated for subset of the cohort
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Kjaergaard 2008 Unable to obtain translation
Knight 1990 Review article
Knight 2001 Validation of a specific assay
Knight 2005 Less than 80% of pregnancies had gestational age confirmed by ultrasound scan
Koos 2006 Review article
Kornman 1996 Less than 5 Down’s syndrome pregnancies in population
Kornman 1997 Unable to extract useful information
Kotaska 2007 No new data
Kramer 1998 No Down’s syndrome pregnancies in study population
Krantz 1996 Modelled data
Krantz 2005 Adjustment factor
Krantz 2007 Uses data from other published studies
Kulch 1993 No Down’s cases in population
Lai 1998 Modelled population
Lai 2003 No Down’s syndrome pregnancies in study population
Laigaard 2006a Unable to extract useful data
Laigaard 2006b Simulation
Lam 1997 Unable to extract useful data
Lam 1998 Fewer than 80% pregnancies had gestational age estimated by USS
Lam 1999a No Down’s syndrome pregnancies in population
Lam 1999b Unable to extract useful data
Lam 2000 Study of women’s decisions about screening
Lam 2001 Male versus female fetuses
Lambert-Messerlian 1996 Fewer than 80% of pregnancies USS dated
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Lambert-Messerlian 1998 Unable to extract useful data
Lauria 2007 No diagnostic data
Lehavi 2005 Down’s syndrome pregnancies only
Leung 2006 Unable to separate twins from singletons therefore unable to extract useful data
Leymarie 1993 Appears to be a review article (French)
Li 1998 Unable to obtain translation
Li 1999 Unable to obtain translation
Li 2010 No diagnostic data
Liao 1997 Unable to obtain translation
Liao 2001 Unable to extract useful data
Lim 2002 Second trimester ultrasound
Lippman 1987 Editorial
Liu 2010 Not possible to separate out data for cases of Down’s syndrome
Lo 2010 Pooled test results
Lustig 1988 Gestational age by LMP only
Luthgens 2008 FPR and DR obtained from different cohorts
MacDonald 1991 Fewer than 80% of gestational ages estimated by USS
Macintosh 1994 Unable to extract useful data
Macintosh 1997 Unable to extract useful data
MacRae 2010 Pooled test results
Macri 1994 Likely fewer than 80% evaluated for gestational age by ultrasound examination
Macri 1996 Likely fewer than 80% evaluated for gestational age by ultrasound examination
Malone 1998 Review article
Malone 2003 Review article
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Mandryka-Stankewycz 2009 No diagnostic data
Mangione 2001 Abnormal screening results only
Markov 2008 Unable to obtain paper
Maymon 2001a No Down’s syndrome pregnancies in study population
Maymon 2001b No normal test results included therefore unable to extract meaningful data
Maymon 2002 No Down’s syndrome pregnancies in study population
Maymon 2004 No Down’s syndrome pregnancies in study population
Maymon 2005 Modelled data
McDuffie 1996 USS dating on screen positive women only
Meier 2002 Observed versus expected cases of Down’s syndrome in a population
Merkatz 1984 Gestational age not confirmed by ultrasound scan
Merz 2005 Editorial
Merz 2008 First trimester only
Metzenbauer 2001 Normal pregnancies only
Metzenbauer 2002 Unable to extract useful data
Mikic 1999 No Down’s syndrome pregnancies in study population
Miller 1991 Unable to extract useful data
Milunsky 1989 Fewer than 80% gestational age estimated by USS
Milunsky 1996 Fewer than 80% gestational age estimated by USS
Minobe 2002 Gestational age greater than specified limits
Miron 2008 No diagnostic data
Miron 2009 No diagnostic data
Miron 2010 No diagnostic data
Miyamura 1999 Unable to extract useful data
102First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Moghadam 1998 Unable to extract useful data
Monni 2000 Less than 5 Down’s syndrome pregnancies
Monni 2002 Review article
Mooney 1994 Greater than 24 weeks’ gestation
Muhcu 2008 No diagnostic data
Muller 1994 No Down’s syndrome pregnancies in study population
Muller 1996 Unable to extract useful data
Muller 1999 Unable to extract useful data
Muller 2002a Gestational age greater than 24 weeks
Muller 2002b Unable to extract meaningful data - unable to separate double and triple test data
Muller 2003 No Down’s syndrome pregnancies in study population
Murta 2002 Unable to extract useful data
Musone 2000 Unable to extract useful data
Musto 1986 Fewer than 80% USS dated
Myrick 1990 Unable to extract useful data
Naidoo 2008 Not specific Down’s syndrome results
Nau 2009 No diagnostic data
Nau 2009a No diagnostic data
Neveux 1996a No Down’s syndrome pregnancies in population
Neveux 1996b Unable to extract useful data
Ng 2004 Unable to extract useful data
Nicolaides 1992 Study of outcomes of abnormal NT results
Nicolaides 2000 Review article
Nicolaides 2004 Review article
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Nicolaides 2005a Unable to obtain translation - appears to be a review article
Nicolaides 2005b Unable to obtain translation - appears to be a review article
Nicolaides 2005c Unable to obtain translation - appears to be a review article
Nicolaides 2005d Unable to obtain translation - appears to be a review article
Nicolaides 2005e Unable to obtain translation - appears to be a review article
Nicolaides 2005f Review article
Niemimaa 2001 No Down’s pregnancies in study population
Niemimaa 2002 No Down’s syndrome pregnancies in population
Niemimaa 2003 No Down’s syndrome pregnancies in population
Noble 1997 Unable to extract useful data
Norgaard 1990 Less than 80% of gestational ages confirmed by USS
Norton 1992 Unable to extract useful data
Novakov-Mikic 2007 Out of FT screening time frame
O’Brien 1997a No Down’s syndrome pregnancies in population
O’Brien 1997b No Down’s syndrome pregnancies in population
Odibo 2004 Gestational age of greater than 14 weeks in USS population
Odibo 2007 ST ultrasound
Odibo 2008 ST ultrasound
Odibo 2009 No results presented
Offerdal 2008 ST ultrasound
Ognibene 1999 Unable to extract useful data
Oh 2007 No diagnostic data
Olajide 1989 Unable to extract useful data
Onda 1996 Unable to extract useful data
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Onda 1998 Unable to extract useful data
Onda 2000 Less than 80% follow-up
Orlandi 2002 No Down’s syndrome pregnancies in study population
Ottavio 1997 Second trimester USS
Ozkaya 2010 Only healthy pregnancies
Paladini 2007 No diagnostic data
Palka 1998 Twin data used in calculation of the median
Palomaki 1989 Fewer than 80% USS dated
Palomaki 1993 No Down’s syndrome pregnancies in population
Palomaki 1994 No Down’s syndrome pregnancies in population
Palomaki 1996 Meta-analysis
Palomaki 2005 Unable to extract meaningful data
Panburana 2001 Less than 5 Down’s syndrome pregnancies in population
Pandya 1994 Study of outcomes of abnormal NT results
Pandya 1995b Review article
Papadopoulou 2008 No diagnostic data
Parra-Cordero 2007 ST ultrasound
Paterlini-Brechot 2007 Editorial, no new data
Paul 2001 Unable to extract useful data
Peralta 2005 Unable to extract useful data
Perenc 1998 No Down’s syndrome pregnancies in study population
Perheentupa 2002 No Down’s syndrome pregnancies in population
Perona 1998 Smokers versus non smokers
Persico 2008 ST ultrasound
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Petervari 2000 Unable to extract useful data
Petrocik 1989 Likely fewer than 80% USS dated
Phillips 1992 Gestational age confirmed by USS in less than 80% of population
Phillips 1993 Gestational age confirmed by USS in less than 80% of population
Pihl 2008 Only 2 cases of Down’s syndrome
Pinette 2003 Women screened prior to recruitment
Platt 2004 Unable to extract useful data
Podobnik 1995 Abnormal results only
Poon 2009 No diagnostic data
Prefumo 2002 Comparison of prevalence and prediction
Prefumo 2004 Comparison of a marker in women of different ethnic origins
Price 1998 Unable to extract useful data
Páez 2004 Unable to obtain translation
Rembouskos 2004 Unable to extract useful data
Ren 1992 Review article
Renier 1998 Method of ascertainment of gestational age unclear
Twin gestations included in general population
Resta 1990 Second trimester USS
Reynders 1997 Fewer than 5 Down’s cases
Reynolds 1989 Explanation of mathematical techniques
Reynolds 1999 Unable to extract useful data
Reynolds 2008 Not full diagnostic data
Ribbert 1996 No Down’s syndrome pregnancies in study population
Rice 2005 Down’s syndrome pregnancies excluded from study
Rich 1991 Unable to extract useful data
106First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Roberts 1995 No Down’s syndrome pregnancies in study population
Robertson 1991 Editorial
Rode 2003 No Down’s pregnancies
Ronge 2006 Editorial - summary of FASTER results
Rose 1995 Review article
Ross 1997 Review article
Rotmensch 1996 Unable to extract useful data
Rotmensch 1999 No Down’s syndrome pregnancies in study population
Rozenberg 2006 USS greater than 14 weeks’ gestation
Rudnicka 2002 No Down’s syndrome pregnancies in population
Ryall 1992 Unable to determine method of confirmation of gestational age
Ryall 2001 High-risk results only included (i.e. no screen negative group for comparison)
Räty 2000 No Down’s syndrome pregnancies in population
Räty 2002 No Down’s pregnancies in population
Sabriá 2002 Unable to ascertain how numbers calculated and from which populations
Sacchini 2003 Unable to extract useful data
Sahota 2009 No diagnostic data
Sahota 2010 Included in Sahota 2010
Salazar 2007 Unable to obtain paper
Salazar 2008 Only 1 case of Down’s syndrome
Saller 1997 Down’s syndrome secondary to Robertsonian translocation only. No controls
Salomon 2001 No Down’s syndrome pregnancies in population
Salonen 1997 Fewer than 80% had gestational age estimated by USS
Saltvedt 2005 Gestation greater than 14 weeks for nuchal scanning
107First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Saridogan 1996 Down’s syndrome and Edward’s syndrome affected pregnancies only
Savoldelli 1993 Unable to extract useful data
Schielen 2009 Full study information not given
Schiott 2006 Unable to extract useful data
Schmidt 2007a Not specific to Down’s syndrome
Schmidt 2007b No separate Down’s syndrome data
Schmidt 2007c No diagnostic data
Schmidt 2008a Not specific to Down’s syndrome
Schmidt 2008b Not specific to Down’s syndrome
Schmidt 2008c Not specific to Down’s syndrome
Schmidt 2010 No follow-up data for test negatives
Schuchter 1998 No Down’s pregnancies in study population
Scott 1995 Less than 5 Down’s syndrome pregnancies in study population
Seeds 1990 Review article
Seki 1995 No Down’s syndrome pregnancies in study population
Shenhav 2003 No Down’s syndrome pregnancies
Shintaku 1989 Unable to extract useful data
Shulman 2003 No Down’s syndrome pregnancies in population
Sieroszewski 2008 No Down’s syndrome specific information for specificity
Simon-Bouy 1999 Review article
Simpson 1986 Gestational age confirmed by USS in less than 80% of population
Smith 1990 Analysis of screen positive results
Smith 1996 Review/meta-analysis
Smith 1999 Unable to extract useful data
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Smith-Bindman 2001 Meta-analysis of second trimester ultrasound markers
Smith-Bindman 2003 Population study, not examining DTA
Snijders 1995 Study of prevalence, not screening
Snijders 1999 Study of prevalence, not screening
Soergel 2006 Less than 80% follow-up
Sokol 1998 Observation of Down’s prevalence stratified by age
Sonek 2003 Editorial
Sonek 2007 ST ultrasound
Sood 2010 No diagnostic data
Sooklim 2010 ST ultrasound
Spencer 1985 Fewer than 80% USS dated
Spencer 1991a Likely fewer than 80% USS dated
Spencer 1991b Unable to extract useful data
Spencer 1992 Unable to extract useful data
Spencer 1993a Fewer than 80% USS dated
Spencer 1993b No Down’s pregnancies in study population
Spencer 1993c Unable to extract useful data
Spencer 1993d Fewer than 80% of pregnancies had gestational age confirmed by USS
Spencer 1993e Unable to extract useful data
Spencer 1995 No Down’s pregnancies in population
Spencer 1996 Fewer than 80% of pregnancies had gestational age confirmed by USS
Spencer 1997 Statistical modelling, aneuploid pregnancies only in study population
Spencer 1998a No Down’s pregnancies in population
Spencer 1998b Unable to extract useful data
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Spencer 1999a Review
Spencer 1999b Statistical methods paper
Spencer 2000a Examination of median shifts rather than an evaluation of screening
Spencer 2000b No Down’s syndrome pregnancies in population
Spencer 2000c No Down’s syndrome pregnancies in population
Spencer 2000d No Down’s cases
Spencer 2000e Male versus female fetuses
Spencer 2000f No Down’s cases in population
Spencer 2000g No Down’s pregnancies in population
Spencer 2000h No Down’s pregnancies in population
Spencer 2000i Comparsison of fetal sex
Spencer 2001a No Down’s syndrome pregnancies in population
Spencer 2001b Unable to extract useful data
Spencer 2001c Unable to extract useful data
Spencer 2001d Unable to extract useful data
Spencer 2001e No Down’s syndrome pregnancies in population
Spencer 2002a No Down’s pregnancies
Spencer 2002b Risk validation study
Spencer 2002c No Down’s syndrome pregnancies in population
Spencer 2002d Demonstration of median changes with time, rather than evaluation of screening
Spencer 2003a No Down’s pregnancies in population
Spencer 2003b No Down’s pregnancies in population
Spencer 2003c Calculation of weight correction factor
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Spencer 2003d Fewer than 5 Down’s syndrome pregnancies
Spencer 2004 Calculation of smoking correction factor
Spencer 2005a No Down’s pregnancies
Spencer 2005b No Down’s pregnancies
Spencer 2005c Comparison of two different assays - not actual screening evaluation
Spencer 2008b Unable to extract appropriate data for unaffected pregnancies
Spong 1999 Comparison of male and female fetuses
Staboulidou 2009 No diagnostic data
Stevens 1998 Literature review
Stoll 1992 Review article
Stressig 2011 ST ultrasound
Su 2002 Unable to extract useful data
Suchet 1995 Review article
Suchy 1990 Unable to ascertain method of confirmation of gestational age
Summers 2003a Only 55% gestational ages estimated by USS
Summers 2003b No Down’s syndrome pregnancies in study population
Suntharasaj 2005 Examination of inter-observer variation in NT scanning
Susman 2010 No diagnostic data
Sutton 2004 Unable to extract useful data
Suzuki 1998 Unable to extract useful data
Tabor 1987 Geststional age not confirmed by USS
Tanski 1999 Information on screen positive pregnancies only
Thilaganathan 1998 No Down’s syndrome pregnancies in study population
Thilaganathan 1999 Editorial
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Tislaric 2002 No Down’s syndrome pregnancies in population
Torok 1997 Unable to extract useful data
Torring 2009 Not possible to obtain full diagnostic data
Trninic-Pjevic 2007 Unable to obtain translation
Tsai 2001 Less than 5 Down’s syndrome pregnancies in study population
Valerio 1996 Fewer than 80% pregnancies had gestational age estimated by USS
Van Blerk 1992 Unable to extract useful data
Van Dyke 2007 Not possible to obtain full diagnostic data
Van Heesch, 2006 No Down’s syndrome pregnancies in study population
Software comparison study
Van Lith 1991 Unable to extract useful data
Van Lith 1993 Unable to extract useful data
Van Lith 1994 Unable to extract useful data
Veress 1986 Unable to extract useful data
Veress 1988 Unable to extract useful data
Vergani 2008 ST ultrasound
Vintzileos 2003 Second trimester USS
Wald 1988a Less than 80% had gestational age confirmed by ultrasound
Wald 1988b Gestational age not confirmed by USS
Wald 1991 No Down’s pregnancies in study
Wald 1992a Less than 80% had gestational age confirmed by ultrasound
Wald 1992b No Down’s pregnancies in study
Wald 1992c No Down’s pregnancies in study
Wald 1993 No USS dating
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Wald 1994a No Down’s syndrome pregnancies in population
Wald 1994b Review article
Wald 1996a No Down’s pregnancies
Wald 1996b Dated by LMP
Wald 1996c No Down’s syndrome pregnancies in population
Wald 1996d Gestational age greater than 24 weeks
Wald 1997 Data modelled on 3 separate populations of women
Wald 1998 Unable to extract useful data
Wald 1999a Unable to extract useful data
Wald 1999b Gestational age not confirmed by USS
Wald 1999c No Down’s syndrome pregnancies
Wald 1999d Modelled on several studies, some of which have no USS dating
Wald 2003c No cases
Wald 2003d Less than 80% had gestational age confirmed by USS
Wald 2006 Modelled on SURRUS data
Wallace 1994 Unable to extract useful data
Wallace 1997 No Down’s syndrome pregnancies in study population
Wang 2010 ST ultrasound
Ward 2005 Review article
Watt 1996 No Down’s syndrome pregnancies in study population
Watt 1996a No Down’s syndrome pregnancies in study population
Wax 2007 No diagnostic data
Weinans 2001 Unable to extract useful data
Weinans 2004 Study of women’s views on screening
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Weisz 2007 Cohort split into people having different tests and non-representative samples of women assessed for
each test
Welborn 1994 Abnormal results only (cystic hygroma)
Wenstrom 1993 Less than 80% of pregnancies had gestational age confirmed by USS
Wenstrom 1995a Adjustment factors
Wenstrom 1995b Less than 80% of pregnancies had gestational age confirmed by USS
Wetta 2011 No diagnostic data
Whitlow 1998a Unable to extract useful data
Whitlow 1998b Unable to extract useful data
Whitlow 1999 Unable to extract useful data
Williamson 1994 Likely fewer than 80% USS dated
Wilson 2000 Review
Wojdemann 2001 No Down’s syndrome pregnancies in study population
Wong 2003 Less than 5 Down’s syndrome pregnancies in population
Wright 2006 Mathematical model
Wright 2007 Simulation study, no new data
Xie 2010 Only cases of false negatives and true negatives included
Yagel 1998 Second trimester USS
Yamamoto 2001a Unable to extract useful data
Yamamoto 2001b Method of determination of gestational age unclear
Yamamoto 2001c Unable to extract useful data
Yaron 2001 Male versus female fetuses
Ye 1995 Unable to obtain translation
Yoshida 2000 Fewer than 80% pregnancies had gestational age estimated by USS
Zalel 2008 No diagnostic data
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Zeitune 1991 Only aneuploid pregnancies included in study
Zelop 2005 No Down’s cases in population
Zhang 2011 No diagnostic data
Zhao 1998 Unable to obtain translation
Zhong 2011 Second trimester ultrasound
Zoppi 2003 Inappropriate study design
CVS: CVS: chorionic villus sampling
FISH: Fluorescence in situ hybridisation
FPR: false positive rate
LMP: last menstrual period
NT: nuchal transparency
SURUSS: Serum, Urine and Ultrasound Screening Study
USS: ultrasound screening
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Age, 1T PAPP-A , 2T free ßhCG
and 2T AFP at 5% FPR
1 1188
2 Age, 1T PAPP-A , 2T free ßhCG
and 2T AFP, risk 1:300
1 1009
3 Age, 1T PAPP-A , 2T total
hCG, and 2T AFP at 5% FPR
1 1188
4 Age, 1T PAPP-A , 2T free
ßhCG, 2T uE3 and 2T AFP at
5% FPR
1 1188
5 Age, 1T PAPP-A , 2T total
hCG, 2T uE3 and 2T AFP at
2% FPR
2 707
6 Age, 1T PAPP-A , 2T total
hCG, 2T uE3 and 2T AFP at
5% FPR
2 1767
7 Age, 1T PAPP-A , 2T total
hCG, 2T uE3 and 2T AFP at
risk 1:200
2 707
8 Age, 1T PAPP-A , 2T total
hCG, 2T uE3 and 2T AFP,
mixed cutpoints
4 2474
9 Age, 1T PAPP-A , 2T free
ßhCG, 2T uE3, 2T AFP and
2T Inhibin A at 5% FPR
1 1188
10 Age, 1T PAPP-A , 2T free
ßhCG, 2T uE3, 2T AFP and
2T Inhibin A at risk 1:50
1 1188
11 Age, 1T PAPP-A , 2T free
ßhCG, 2T uE3, 2T AFP and
2T Inhibin A at risk 1:100
1 1188
12 Age, 1T PAPP-A , 2T free
ßhCG, 2T uE3, 2T AFP and
2T Inhibin A at risk 1:150
1 1188
13 Age, 1T PAPP-A , 2T free
ßhCG, 2T uE3, 2T AFP and
2T Inhibin A at risk 1:200
1 1188
14 Age, 1T PAPP-A , 2T free
ßhCG, 2T uE3, 2T AFP and
2T Inhibin A at risk 1:250
1 1188
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15 Age, 1T PAPP-A , 2T free
ßhCG, 2T uE3, 2T AFP and
2T Inhibin A at risk 1:300
1 1188
16 Age, 1T PAPP-A , 2T total
hCG, 2T uE3, 2T AFP and 2T
Inhibin A at 5% FPR
2 34821
17 Age, 1T PAPP-A , 2T total
hCG, 2T uE3, 2T AFP and 2T
Inhibin A at risk 1:100
1 540
18 Age, 1T PAPP-A , 2T total
hCG, 2T uE3, 2T AFP and 2T
Inhibin A at risk 1:150
1 540
19 Age, 1T PAPP-A , 2T total
hCG, 2T uE3, 2T AFP and 2T
Inhibin A at risk 1:200
1 540
20 Age, 1T PAPP-A , 2T total
hCG, 2T uE3, 2T AFP and 2T
Inhibin A at risk 1:250
1 540
21 Age, 1T PAPP-A , 2T total
hCG, 2T uE3, 2T AFP and 2T
Inhibin A, mixed cutpoints
3 35361
22 Age, 1T PAPP-A , 2T total
hCG, 2T uE3, 2T AFP and 2T
PAPP-A at 2% FPR
2 707
23 Age, 1T PAPP-A , 2T total
hCG, 2T uE3, 2T AFP and 2T
PAPP-A at risk 1:200
2 707
24 Age, 1T PAPP-A , 2T total
hCG, 2T uE3, 2T AFP, 2T
Inhibin A and 2T PAPP-A at
risk 1:100
1 540
25 Age, 1T PAPP-A , 2T total
hCG, 2T uE3, 2T AFP, 2T
Inhibin A and 2T PAPP-A at
risk 1:150
1 540
26 Age, 1T PAPP-A , 2T total
hCG, 2T uE3, 2T AFP, 2T
Inhibin A and 2T PAPP-A at
risk 1:200
1 540
27 Age, 1T PAPP-A , 2T total
hCG, 2T uE3, 2T AFP, 2T
Inhibin A and 2T PAPP-A at
risk 1:250
1 540
28 Age, 1T PAPP-A , 1T total
hCG, 2T total hCG, 2T uE3
and 2T AFP at 2% FPR
2 707
29 Age, 1T PAPP-A , 1T total
hCG, 2T total hCG, 2T uE3
and 2T AFP at risk 1:200
2 707
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30 Age, 1T PAPP-A , 1T uE3, 2T
total hCG, 2T uE3 and 2T
AFP at 2% FPR
2 707
31 Age, 1T PAPP-A , 1T uE3, 2T
total hCG, 2T uE3 and 2T
AFP at risk 1:200
2 707
32 Age, 1T PAPP-A , 1T total
hCG, 1T uE3, 2T total hCG,
2T uE3, 2T AFP and 2T
PAPP-A at 2% FPR
2 707
33 Age, 1T PAPP-A , 1T total
hCG, 1T uE3, 2T total hCG,
2T uE3, 2T AFP and 2T
PAPP-A at risk 1:200
2 707
34 Age, 1T AFP, 1T free ßhCG,
1T uE3, 2T total hCG, 2T
uE3 and 2T AFP at risk 1:250
1 12339
35 Age, 1T AFP, 1T free ßhCG,
1T uE3, 2T total hCG, 2T
uE3 and 2T AFP at risk 1:384
1 12339
36 Age, 1T NT, 2T total hCG and
2T AFP, 5FPR
2 17347
37 Age, 1T NT, 2T total hCG and
2T AFP, risk 1:250
2 5446
38 Age, 1T NT, 2T total hCG and
2T AFP, mixture cutpoint
4 22793
39 Age, 1T NT, 2T free ßhCG
and 2T AFP, 5FPR
2 6616
40 Age, 1T NT, 2T free ßhCG
and 2T AFP, mixture cutpoint
2 6616
41 Age, 1T NT, 2T free ßhCG,
2T uE3 and 2T AFP, 5FPR
1 1110
42 Age, 1T NT, 2T total hCG, 2T
uE3 and 2T AFP, 5FPR
1 1110
43 Age, 1T NT, 2T total hCG, 2T
uE3 and 2T AFP, risk 1:250
2 3256
44 Age, 1T NT, 2T total hCG,
2T uE3 and 2T AFP, mixture
cutpoint
4 13708
45 Age, 1T NT, 2T total hCG, 2T
uE3, 2T AFP and 2T Inhibin
A, 5FPR
1 1110
46 Age, 1T NT, 2T free ßhCG, 2T
uE3, 2T AFP and 2T Inhibin
A, 5FPR
1 1110
47 Age, 1T NT, 2T free ßhCG, 2T
uE3, 2T AFP and 1T PAPP-A ,
5FPR
1 1110
48 Age, 1T NT, 2T free ßhCG, 2T
uE3, 2T AFP and 1T PAPP-A ,
risk 1:250
1 390
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49 Age, 1T NT, 1T PAPP-A , 2T
total hCG and 2T AFP, 5FPR
1 1110
50 Age, 1T NT, 1T PAPP-A , 2T
free ßhCG and 2T AFP, 5FPR
1 1110
51 Age, 1T NT, 1T PAPP-A , 2T
free ßhCG and 2T AFP,risk
1:250
1 390
52 Age, 1T NT, 1T PAPP-A , 2T
free ßhCG and 2T AFP, risk
1:300
1 2290
53 Age, 1T NT, 1T PAPP-A, 2T
total hCG, 2T uE3 and 2T
AFP 5FPR
1 1110
54 Age, 1T NT, 1T PAPP-A , 2T
total hCG, 2T uE3 and 2T
AFP, risk 1:200
1 32227
55 Age, 1T NT, 1T PAPP-A, 2T
total hCG, 2T uE3 and 2T
AFP, mixed cutpoints
2 33337
56 Age, 1T NT, 1T PAPP-A , 2T
total hCG, 2T uE3, 2T AFP
and 2T Inhibin A, 5FPR
2 34743
57 Age, 1T NT, 1T PAPP-A , 2T
total hCG, 2T uE3, 2T AFP
and 2T Inhibin A, risk 1:150
1 4927
58 Age, 1T NT, 1T PAPP-A ,
2T total hCG, 2T uE3, 2T
AFP and 2T Inhibin A, mixed
cutpoints
3 39670
59 Age, 1T NT, 1T PAPP-A , 2T
free ßhCG, 2T uE3, 2T AFP
and 2T Inhibin A,risk 1:300
1 390
60 Age, 1T NT, 1T PAPP-A , 2T
free ßhCG, 2T uE3, 2T AFP
and 2T Inhibin A, 1:270
1 7842
61 Age, 1T NT, 1T PAPP-A , 2T
free ßhCG, 2T uE3, 2T AFP
and 2T Inhibin A,risk 1:250
1 390
62 Age, 1T NT, 1T PAPP-A , 2T
free ßhCG, 2T uE3, 2T AFP
and 2T Inhibin A,risk 1:200
1 390
63 Age, 1T NT, 1T PAPP-A , 2T
free ßhCG, 2T uE3, 2T AFP
and 2T Inhibin A,risk 1:150
2 9759
64 Age, 1T NT, 1T PAPP-A , 2T
free ßhCG, 2T uE3, 2T AFP
and 2T Inhibin A,risk 1:100
1 390
65 Age, 1T NT, 1T PAPP-A , 2T
free ßhCG, 2T uE3, 2T AFP
and 2T Inhibin A,risk 1:50
1 390
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66 Age, 1T NT, 1T PAPP-A , 2T
free ßhCG, 2T uE3, 2T AFP
and 2T Inhibin A, 5FPR
3 31698
67 Age, 1T NT, 1T PAPP-A , 2T
free ßhCG, 2T uE3, 2T AFP
and 2T Inhibin A, 3FPR
1 22746
68 Age, 1T NT, 1T PAPP-A , 2T
free ßhCG, 2T uE3, 2T AFP
and 2T Inhibin A, 1FPR
1 22746
69 Age, 1T NT, 1T PAPP-A ,
2T free ßhCG, 2T uE3, 2T
AFP and 2T Inhibin A, mixed
cutpoints
4 40348
70 Age, 1T NT, 1T PAPP-A, 1T
free ßhCG, 2T total hCG, 2T
uE3 and 2T AFP, risk 1:250
1 5060
71 Age, 1T NT, 1T PAPP-A, 1T
free ßhCG, 2T uE3, 2T AFP,
2T total hCG and 2T Inhibin
A, risk 1:150
1 33546
72 ADAM 12 2T TO 1T RATIO 1 579
73 Stepwise: Age, 1T NT, 1T
PAPP-A , 1T free ßhCG, if risk
<1/30, 2T total hCG, 2T uE3,
2T AFP and 2T Inhibin A risk
1:270
1 32355
74 Stepwise: Age, 1T NT, 1T
PAPP-A , 1T free ßhCG, if risk
<1/30, 2T free ßhCG, 2T uE3,
2T AFP and 2T Inhibin A risk
1:270
1 7842
75 Stepwise: Age, 1T NT, 1T
PAPP-A , 1T free ßhCG, if risk
<1/30, 2T free ßhCG, 2T uE3,
2T AFP and 2T Inhibin A 5%
FPR
1 7842
76 Stepwise: Age, 1T NT, 1T
PAPP-A , if risk <1:100, 2T
free ßhCG, 2T uE3, 2T AFP,
risk 1:250
1 1507
77 Contingent: Age, 1T NT, 1T
PAPP-A , 1T free ßhCG, if
risk 1/30-1/1500, 2T total
hCG, 2T uE3, 2T AFP and 2T
Inhibin A risk 1:270
1 32355
78 Contingent: Age, 1T NT, 1T
PAPP-A , 1T free ßhCG, if risk
1/30-1/1500, 2T free ßhCG,
2T uE3, 2T AFP and 2T
Inhibin A risk 1:270
1 7842
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79 Contingent: Age, 1T NT, 1T
PAPP-A , 1T free ßhCG, if risk
1/30-1/1500, 2T free ßhCG,
2T uE3, 2T AFP and 2T
Inhibin A 5%FPR
1 7842
Test 1. Age, 1T PAPP-A , 2T free ßhCG and 2T AFP at 5% FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 1 Age, 1T PAPP-A , 2T free hCG and 2T AFP at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 83 55 15 1035 0.85 [ 0.76, 0.91 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 2. Age, 1T PAPP-A , 2T free ßhCG and 2T AFP, risk 1:300.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 2 Age, 1T PAPP-A , 2T free hCG and 2T AFP, risk 1:300
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rodrigues 2009 5 60 1 943 0.83 [ 0.36, 1.00 ] 0.94 [ 0.92, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 3. Age, 1T PAPP-A , 2T total hCG, and 2T AFP at 5% FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 3 Age, 1T PAPP-A , 2T total hCG, and 2T AFP at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 81 55 17 1035 0.83 [ 0.74, 0.90 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 4. Age, 1T PAPP-A , 2T free ßhCG, 2T uE3 and 2T AFP at 5% FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 4 Age, 1T PAPP-A , 2T free hCG, 2T uE3 and 2T AFP at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 84 55 14 1035 0.86 [ 0.77, 0.92 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 5. Age, 1T PAPP-A , 2T total hCG, 2T uE3 and 2T AFP at 2% FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 5 Age, 1T PAPP-A , 2T total hCG, 2T uE3 and 2T AFP at 2% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wright 2010 FASTER trial 57 8 21 382 0.73 [ 0.62, 0.82 ] 0.98 [ 0.96, 0.99 ]
Wright 2010 North York 37 4 6 192 0.86 [ 0.72, 0.95 ] 0.98 [ 0.95, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 6. Age, 1T PAPP-A , 2T total hCG, 2T uE3 and 2T AFP at 5% FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 6 Age, 1T PAPP-A , 2T total hCG, 2T uE3 and 2T AFP at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Baviera 2010 12 28 5 534 0.71 [ 0.44, 0.90 ] 0.95 [ 0.93, 0.97 ]
Wald 2003b 83 55 15 1035 0.85 [ 0.76, 0.91 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 7. Age, 1T PAPP-A , 2T total hCG, 2T uE3 and 2T AFP at risk 1:200.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 7 Age, 1T PAPP-A , 2T total hCG, 2T uE3 and 2T AFP at risk 1:200
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wright 2010 FASTER trial 62 14 16 376 0.79 [ 0.69, 0.88 ] 0.96 [ 0.94, 0.98 ]
Wright 2010 North York 38 6 5 190 0.88 [ 0.75, 0.96 ] 0.97 [ 0.93, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 8. Age, 1T PAPP-A , 2T total hCG, 2T uE3 and 2T AFP, mixed cutpoints.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 8 Age, 1T PAPP-A , 2T total hCG, 2T uE3 and 2T AFP, mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Baviera 2010 12 28 5 534 0.71 [ 0.44, 0.90 ] 0.95 [ 0.93, 0.97 ]
Wald 2003b 83 55 15 1035 0.85 [ 0.76, 0.91 ] 0.95 [ 0.93, 0.96 ]
Wright 2010 FASTER trial 62 14 16 376 0.79 [ 0.69, 0.88 ] 0.96 [ 0.94, 0.98 ]
Wright 2010 North York 38 6 5 190 0.88 [ 0.75, 0.96 ] 0.97 [ 0.93, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 9. Age, 1T PAPP-A , 2T free ßhCG, 2T uE3, 2T AFP and 2T Inhibin A at 5% FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 9 Age, 1T PAPP-A , 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 88 55 10 1035 0.90 [ 0.82, 0.95 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 10. Age, 1T PAPP-A , 2T free ßhCG, 2T uE3, 2T AFP and 2T Inhibin A at risk 1:50.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 10 Age, 1T PAPP-A , 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A at risk 1:50
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 69 12 29 1078 0.70 [ 0.60, 0.79 ] 0.99 [ 0.98, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 11. Age, 1T PAPP-A , 2T free ßhCG, 2T uE3, 2T AFP and 2T Inhibin A at risk 1:100.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 11 Age, 1T PAPP-A , 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A at risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 75 24 23 1066 0.77 [ 0.67, 0.85 ] 0.98 [ 0.97, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 12. Age, 1T PAPP-A , 2T free ßhCG, 2T uE3, 2T AFP and 2T Inhibin A at risk 1:150.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 12 Age, 1T PAPP-A , 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A at risk 1:150
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 79 35 19 1055 0.81 [ 0.71, 0.88 ] 0.97 [ 0.96, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 13. Age, 1T PAPP-A , 2T free ßhCG, 2T uE3, 2T AFP and 2T Inhibin A at risk 1:200.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 13 Age, 1T PAPP-A , 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A at risk 1:200
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 81 45 17 1045 0.83 [ 0.74, 0.90 ] 0.96 [ 0.95, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 14. Age, 1T PAPP-A , 2T free ßhCG, 2T uE3, 2T AFP and 2T Inhibin A at risk 1:250.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 14 Age, 1T PAPP-A , 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A at risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 83 55 15 1035 0.85 [ 0.76, 0.91 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
126First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 15. Age, 1T PAPP-A , 2T free ßhCG, 2T uE3, 2T AFP and 2T Inhibin A at risk 1:300.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 15 Age, 1T PAPP-A , 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A at risk 1:300
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 84 63 14 1027 0.86 [ 0.77, 0.92 ] 0.94 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 16. Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A at 5% FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 16 Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A at 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Malone 2005 75 1677 12 31869 0.86 [ 0.77, 0.93 ] 0.95 [ 0.95, 0.95 ]
Wald 2003b 87 55 11 1035 0.89 [ 0.81, 0.94 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 17. Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A at risk 1:100.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 17 Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A at risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Palomaki 2006 22 10 10 498 0.69 [ 0.50, 0.84 ] 0.98 [ 0.96, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 18. Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A at risk 1:150.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 18 Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A at risk 1:150
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Palomaki 2006 24 14 8 494 0.75 [ 0.57, 0.89 ] 0.97 [ 0.95, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 19. Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A at risk 1:200.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 19 Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A at risk 1:200
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Palomaki 2006 24 17 8 491 0.75 [ 0.57, 0.89 ] 0.97 [ 0.95, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 20. Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A at risk 1:250.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 20 Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A at risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Palomaki 2006 24 21 8 487 0.75 [ 0.57, 0.89 ] 0.96 [ 0.94, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 21. Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A, mixed cutpoints.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 21 Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A, mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Malone 2005 75 1677 12 31869 0.86 [ 0.77, 0.93 ] 0.95 [ 0.95, 0.95 ]
Palomaki 2006 24 21 8 487 0.75 [ 0.57, 0.89 ] 0.96 [ 0.94, 0.97 ]
Wald 2003b 87 55 11 1035 0.89 [ 0.81, 0.94 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 22. Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T PAPP-A at 2% FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 22 Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T PAPP-A at 2% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wright 2010 FASTER trial 55 8 23 382 0.71 [ 0.59, 0.80 ] 0.98 [ 0.96, 0.99 ]
Wright 2010 North York 37 4 6 192 0.86 [ 0.72, 0.95 ] 0.98 [ 0.95, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 23. Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T PAPP-A at risk 1:200.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 23 Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T PAPP-A at risk 1:200
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wright 2010 FASTER trial 55 9 23 381 0.71 [ 0.59, 0.80 ] 0.98 [ 0.96, 0.99 ]
Wright 2010 North York 39 3 4 193 0.91 [ 0.78, 0.97 ] 0.98 [ 0.96, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 24. Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP, 2T Inhibin A and 2T PAPP-A at risk 1:100.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 24 Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP, 2T Inhibin A and 2T PAPP-A at risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Palomaki 2006 24 7 8 501 0.75 [ 0.57, 0.89 ] 0.99 [ 0.97, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 25. Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP, 2T Inhibin A and 2T PAPP-A at risk 1:150.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 25 Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP, 2T Inhibin A and 2T PAPP-A at risk 1:150
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Palomaki 2006 25 11 7 497 0.78 [ 0.60, 0.91 ] 0.98 [ 0.96, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 26. Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP, 2T Inhibin A and 2T PAPP-A at risk 1:200.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 26 Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP, 2T Inhibin A and 2T PAPP-A at risk 1:200
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Palomaki 2006 26 17 6 491 0.81 [ 0.64, 0.93 ] 0.97 [ 0.95, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 27. Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP, 2T Inhibin A and 2T PAPP-A at risk 1:250.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 27 Age, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP, 2T Inhibin A and 2T PAPP-A at risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Palomaki 2006 27 19 5 489 0.84 [ 0.67, 0.95 ] 0.96 [ 0.94, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 28. Age, 1T PAPP-A , 1T total hCG, 2T total hCG, 2T uE3 and 2T AFP at 2% FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 28 Age, 1T PAPP-A , 1T total hCG, 2T total hCG, 2T uE3 and 2T AFP at 2% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wright 2010 FASTER trial 55 8 23 382 0.71 [ 0.59, 0.80 ] 0.98 [ 0.96, 0.99 ]
Wright 2010 North York 36 4 7 192 0.84 [ 0.69, 0.93 ] 0.98 [ 0.95, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 29. Age, 1T PAPP-A , 1T total hCG, 2T total hCG, 2T uE3 and 2T AFP at risk 1:200.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 29 Age, 1T PAPP-A , 1T total hCG, 2T total hCG, 2T uE3 and 2T AFP at risk 1:200
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wright 2010 FASTER trial 59 14 19 376 0.76 [ 0.65, 0.85 ] 0.96 [ 0.94, 0.98 ]
Wright 2010 North York 38 6 5 190 0.88 [ 0.75, 0.96 ] 0.97 [ 0.93, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 30. Age, 1T PAPP-A , 1T uE3, 2T total hCG, 2T uE3 and 2T AFP at 2% FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 30 Age, 1T PAPP-A , 1T uE3, 2T total hCG, 2T uE3 and 2T AFP at 2% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wright 2010 FASTER trial 51 8 27 382 0.65 [ 0.54, 0.76 ] 0.98 [ 0.96, 0.99 ]
Wright 2010 North York 35 4 8 192 0.81 [ 0.67, 0.92 ] 0.98 [ 0.95, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 31. Age, 1T PAPP-A , 1T uE3, 2T total hCG, 2T uE3 and 2T AFP at risk 1:200.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 31 Age, 1T PAPP-A , 1T uE3, 2T total hCG, 2T uE3 and 2T AFP at risk 1:200
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wright 2010 FASTER trial 59 16 19 374 0.76 [ 0.65, 0.85 ] 0.96 [ 0.93, 0.98 ]
Wright 2010 North York 38 6 5 190 0.88 [ 0.75, 0.96 ] 0.97 [ 0.93, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 32. Age, 1T PAPP-A , 1T total hCG, 1T uE3, 2T total hCG, 2T uE3, 2T AFP and 2T PAPP-A at 2% FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 32 Age, 1T PAPP-A , 1T total hCG, 1T uE3, 2T total hCG, 2T uE3, 2T AFP and 2T PAPP-A at 2% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wright 2010 FASTER trial 32 8 46 382 0.41 [ 0.30, 0.53 ] 0.98 [ 0.96, 0.99 ]
Wright 2010 North York 24 4 19 192 0.56 [ 0.40, 0.71 ] 0.98 [ 0.95, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 33. Age, 1T PAPP-A , 1T total hCG, 1T uE3, 2T total hCG, 2T uE3, 2T AFP and 2T PAPP-A at risk
1:200.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 33 Age, 1T PAPP-A , 1T total hCG, 1T uE3, 2T total hCG, 2T uE3, 2T AFP and 2T PAPP-A at risk 1:200
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wright 2010 FASTER trial 32 7 46 383 0.41 [ 0.30, 0.53 ] 0.98 [ 0.96, 0.99 ]
Wright 2010 North York 27 3 16 193 0.63 [ 0.47, 0.77 ] 0.98 [ 0.96, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 34. Age, 1T AFP, 1T free ßhCG, 1T uE3, 2T total hCG, 2T uE3 and 2T AFP at risk 1:250.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 34 Age, 1T AFP, 1T free hCG, 1T uE3, 2T total hCG, 2T uE3 and 2T AFP at risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Goh 1996 28 773 6 11532 0.82 [ 0.65, 0.93 ] 0.94 [ 0.93, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 35. Age, 1T AFP, 1T free ßhCG, 1T uE3, 2T total hCG, 2T uE3 and 2T AFP at risk 1:384.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 35 Age, 1T AFP, 1T free hCG, 1T uE3, 2T total hCG, 2T uE3 and 2T AFP at risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Goh 1996 29 1239 5 11066 0.85 [ 0.69, 0.95 ] 0.90 [ 0.89, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 36. Age, 1T NT, 2T total hCG and 2T AFP, 5FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 36 Age, 1T NT, 2T total hCG and 2T AFP, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lam 2002 30 810 5 15392 0.86 [ 0.70, 0.95 ] 0.95 [ 0.95, 0.95 ]
Wald 2003b 70 51 15 974 0.82 [ 0.73, 0.90 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 37. Age, 1T NT, 2T total hCG and 2T AFP, risk 1:250.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 37 Age, 1T NT, 2T total hCG and 2T AFP, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Audibert 2001 9 97 1 3683 0.90 [ 0.55, 1.00 ] 0.97 [ 0.97, 0.98 ]
Benattar 1999 5 75 0 1576 1.00 [ 0.48, 1.00 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 38. Age, 1T NT, 2T total hCG and 2T AFP, mixture cutpoint.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 38 Age, 1T NT, 2T total hCG and 2T AFP, mixture cutpoint
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Audibert 2001 9 97 1 3683 0.90 [ 0.55, 1.00 ] 0.97 [ 0.97, 0.98 ]
Benattar 1999 5 75 0 1576 1.00 [ 0.48, 1.00 ] 0.95 [ 0.94, 0.96 ]
Lam 2002 30 810 5 15392 0.86 [ 0.70, 0.95 ] 0.95 [ 0.95, 0.95 ]
Wald 2003b 70 51 15 974 0.82 [ 0.73, 0.90 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 39. Age, 1T NT, 2T free ßhCG and 2T AFP, 5FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 39 Age, 1T NT, 2T free hCG and 2T AFP, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rozenberg 2002 16 274 4 5212 0.80 [ 0.56, 0.94 ] 0.95 [ 0.94, 0.96 ]
Wald 2003b 71 51 14 974 0.84 [ 0.74, 0.91 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 40. Age, 1T NT, 2T free ßhCG and 2T AFP, mixture cutpoint.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 40 Age, 1T NT, 2T free hCG and 2T AFP, mixture cutpoint
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rozenberg 2002 16 291 4 5195 0.80 [ 0.56, 0.94 ] 0.95 [ 0.94, 0.95 ]
Wald 2003b 71 51 14 974 0.84 [ 0.74, 0.91 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 41. Age, 1T NT, 2T free ßhCG, 2T uE3 and 2T AFP, 5FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 41 Age, 1T NT, 2T free hCG, 2T uE3 and 2T AFP, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 75 51 10 974 0.88 [ 0.79, 0.94 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 42. Age, 1T NT, 2T total hCG, 2T uE3 and 2T AFP, 5FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 42 Age, 1T NT, 2T total hCG, 2T uE3 and 2T AFP, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 74 51 11 974 0.87 [ 0.78, 0.93 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 43. Age, 1T NT, 2T total hCG, 2T uE3 and 2T AFP, risk 1:250.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 43 Age, 1T NT, 2T total hCG, 2T uE3 and 2T AFP, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Babbur 2005 6 73 3 2643 0.67 [ 0.30, 0.93 ] 0.97 [ 0.97, 0.98 ]
Herman 2002 17 12 6 496 0.74 [ 0.52, 0.90 ] 0.98 [ 0.96, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 44. Age, 1T NT, 2T total hCG, 2T uE3 and 2T AFP, mixture cutpoint.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 44 Age, 1T NT, 2T total hCG, 2T uE3 and 2T AFP, mixture cutpoint
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Babbur 2005 6 73 3 2643 0.67 [ 0.30, 0.93 ] 0.97 [ 0.97, 0.98 ]
Herman 2002 17 12 6 496 0.74 [ 0.52, 0.90 ] 0.98 [ 0.96, 0.99 ]
Schuchter 2001 18 652 1 8671 0.95 [ 0.74, 1.00 ] 0.93 [ 0.92, 0.94 ]
Wald 2003b 74 51 11 974 0.87 [ 0.78, 0.93 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 45. Age, 1T NT, 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A, 5FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 45 Age, 1T NT, 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 77 51 8 974 0.91 [ 0.82, 0.96 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 46. Age, 1T NT, 2T free ßhCG, 2T uE3, 2T AFP and 2T Inhibin A, 5FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 46 Age, 1T NT, 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 77 51 8 974 0.91 [ 0.82, 0.96 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 47. Age, 1T NT, 2T free ßhCG, 2T uE3, 2T AFP and 1T PAPP-A , 5FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 47 Age, 1T NT, 2T free hCG, 2T uE3, 2T AFP and 1T PAPP-A , 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 78 51 7 974 0.92 [ 0.84, 0.97 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 48. Age, 1T NT, 2T free ßhCG, 2T uE3, 2T AFP and 1T PAPP-A , risk 1:250.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 48 Age, 1T NT, 2T free hCG, 2T uE3, 2T AFP and 1T PAPP-A , risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 58 11 7 314 0.89 [ 0.79, 0.96 ] 0.97 [ 0.94, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 49. Age, 1T NT, 1T PAPP-A , 2T total hCG and 2T AFP, 5FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 49 Age, 1T NT, 1T PAPP-A , 2T total hCG and 2T AFP, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 77 51 8 974 0.91 [ 0.82, 0.96 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 50. Age, 1T NT, 1T PAPP-A , 2T free ßhCG and 2T AFP, 5FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 50 Age, 1T NT, 1T PAPP-A , 2T free hCG and 2T AFP, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 77 51 8 974 0.91 [ 0.82, 0.96 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 51. Age, 1T NT, 1T PAPP-A , 2T free ßhCG and 2T AFP,risk 1:250.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 51 Age, 1T NT, 1T PAPP-A , 2T free hCG and 2T AFP,risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 57 12 8 313 0.88 [ 0.77, 0.95 ] 0.96 [ 0.94, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 52. Age, 1T NT, 1T PAPP-A , 2T free ßhCG and 2T AFP, risk 1:300.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 52 Age, 1T NT, 1T PAPP-A , 2T free hCG and 2T AFP, risk 1:300
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rodrigues 2009 7 57 1 2225 0.88 [ 0.47, 1.00 ] 0.98 [ 0.97, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 53. Age, 1T NT, 1T PAPP-A, 2T total hCG, 2T uE3 and 2T AFP 5FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 53 Age, 1T NT, 1T PAPP-A, 2T total hCG, 2T uE3 and 2T AFP 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 78 51 7 974 0.92 [ 0.84, 0.97 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 54. Age, 1T NT, 1T PAPP-A , 2T total hCG, 2T uE3 and 2T AFP, risk 1:200.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 54 Age, 1T NT, 1T PAPP-A , 2T total hCG, 2T uE3 and 2T AFP, risk 1:200
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Okun 2008 Integrated 76 992 10 31149 0.88 [ 0.80, 0.94 ] 0.97 [ 0.97, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 55. Age, 1T NT, 1T PAPP-A, 2T total hCG, 2T uE3 and 2T AFP, mixed cutpoints.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 55 Age, 1T NT, 1T PAPP-A, 2T total hCG, 2T uE3 and 2T AFP, mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Okun 2008 Integrated 76 992 10 31149 0.88 [ 0.80, 0.94 ] 0.97 [ 0.97, 0.97 ]
Wald 2003b 78 51 7 974 0.92 [ 0.84, 0.97 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 56. Age, 1T NT, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A, 5FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 56 Age, 1T NT, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Malone 2005 83 1677 4 31869 0.95 [ 0.89, 0.99 ] 0.95 [ 0.95, 0.95 ]
Wald 2003b 79 51 6 974 0.93 [ 0.85, 0.97 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 57. Age, 1T NT, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A, risk 1:150.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 57 Age, 1T NT, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A, risk 1:150
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2009 11 80 1 4835 0.92 [ 0.62, 1.00 ] 0.98 [ 0.98, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 58. Age, 1T NT, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A, mixed cutpoints.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 58 Age, 1T NT, 1T PAPP-A , 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A, mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Malone 2005 83 1677 4 31869 0.95 [ 0.89, 0.99 ] 0.95 [ 0.95, 0.95 ]
Wald 2003b 79 51 6 974 0.93 [ 0.85, 0.97 ] 0.95 [ 0.94, 0.96 ]
Wald 2009 11 80 1 4835 0.92 [ 0.62, 1.00 ] 0.98 [ 0.98, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 59. Age, 1T NT, 1T PAPP-A , 2T free ßhCG, 2T uE3, 2T AFP and 2T Inhibin A,risk 1:300.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 59 Age, 1T NT, 1T PAPP-A , 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A,risk 1:300
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 59 11 6 314 0.91 [ 0.81, 0.97 ] 0.97 [ 0.94, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 60. Age, 1T NT, 1T PAPP-A , 2T free ßhCG, 2T uE3, 2T AFP and 2T Inhibin A, 1:270.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 60 Age, 1T NT, 1T PAPP-A , 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A, 1:270
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Aagaard-Tillery 2009 55 553 4 7230 0.93 [ 0.84, 0.98 ] 0.93 [ 0.92, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 61. Age, 1T NT, 1T PAPP-A , 2T free ßhCG, 2T uE3, 2T AFP and 2T Inhibin A,risk 1:250.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 61 Age, 1T NT, 1T PAPP-A , 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A,risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 59 10 6 315 0.91 [ 0.81, 0.97 ] 0.97 [ 0.94, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 62. Age, 1T NT, 1T PAPP-A , 2T free ßhCG, 2T uE3, 2T AFP and 2T Inhibin A,risk 1:200.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 62 Age, 1T NT, 1T PAPP-A , 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A,risk 1:200
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 58 8 7 317 0.89 [ 0.79, 0.96 ] 0.98 [ 0.95, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 63. Age, 1T NT, 1T PAPP-A , 2T free ßhCG, 2T uE3, 2T AFP and 2T Inhibin A,risk 1:150.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 63 Age, 1T NT, 1T PAPP-A , 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A,risk 1:150
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 57 6 8 319 0.88 [ 0.77, 0.95 ] 0.98 [ 0.96, 0.99 ]
Wald 2009 30 219 5 9115 0.86 [ 0.70, 0.95 ] 0.98 [ 0.97, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 64. Age, 1T NT, 1T PAPP-A , 2T free ßhCG, 2T uE3, 2T AFP and 2T Inhibin A,risk 1:100.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 64 Age, 1T NT, 1T PAPP-A , 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A,risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 55 4 10 321 0.85 [ 0.74, 0.92 ] 0.99 [ 0.97, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
148First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 65. Age, 1T NT, 1T PAPP-A , 2T free ßhCG, 2T uE3, 2T AFP and 2T Inhibin A,risk 1:50.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 65 Age, 1T NT, 1T PAPP-A , 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A,risk 1:50
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003b 53 2 12 323 0.82 [ 0.70, 0.90 ] 0.99 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 66. Age, 1T NT, 1T PAPP-A , 2T free ßhCG, 2T uE3, 2T AFP and 2T Inhibin A, 5FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 66 Age, 1T NT, 1T PAPP-A , 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A, 5FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Aagaard-Tillery 2009 55 389 4 7394 0.93 [ 0.84, 0.98 ] 0.95 [ 0.94, 0.95 ]
Bestwick 2010 100 1132 6 21508 0.94 [ 0.88, 0.98 ] 0.95 [ 0.95, 0.95 ]
Wald 2003b 79 51 6 974 0.93 [ 0.85, 0.97 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 67. Age, 1T NT, 1T PAPP-A , 2T free ßhCG, 2T uE3, 2T AFP and 2T Inhibin A, 3FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 67 Age, 1T NT, 1T PAPP-A , 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A, 3FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bestwick 2010 98 679 8 21961 0.92 [ 0.86, 0.97 ] 0.97 [ 0.97, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 68. Age, 1T NT, 1T PAPP-A , 2T free ßhCG, 2T uE3, 2T AFP and 2T Inhibin A, 1FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 68 Age, 1T NT, 1T PAPP-A , 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A, 1FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bestwick 2010 91 226 15 22414 0.86 [ 0.78, 0.92 ] 0.99 [ 0.99, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 69. Age, 1T NT, 1T PAPP-A , 2T free ßhCG, 2T uE3, 2T AFP and 2T Inhibin A, mixed cutpoints.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 69 Age, 1T NT, 1T PAPP-A , 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A, mixed cutpoints
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Aagaard-Tillery 2009 55 553 4 7230 0.93 [ 0.84, 0.98 ] 0.93 [ 0.92, 0.93 ]
Bestwick 2010 100 1132 6 21508 0.94 [ 0.88, 0.98 ] 0.95 [ 0.95, 0.95 ]
Wald 2003b 59 10 6 315 0.91 [ 0.81, 0.97 ] 0.97 [ 0.94, 0.99 ]
Wald 2009 30 219 6 9115 0.83 [ 0.67, 0.94 ] 0.98 [ 0.97, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 70. Age, 1T NT, 1T PAPP-A, 1T free ßhCG, 2T total hCG, 2T uE3 and 2T AFP, risk 1:250.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 70 Age, 1T NT, 1T PAPP-A, 1T free hCG, 2T total hCG, 2T uE3 and 2T AFP, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Guanciali-Franchi 2010 13 170 0 4877 1.00 [ 0.75, 1.00 ] 0.97 [ 0.96, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 71. Age, 1T NT, 1T PAPP-A, 1T free ßhCG, 2T uE3, 2T AFP, 2T total hCG and 2T Inhibin A, risk 1:150.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 71 Age, 1T NT, 1T PAPP-A, 1T free hCG, 2T uE3, 2T AFP, 2T total hCG and 2T Inhibin A, risk 1:150
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Malone 2005 82 3680 5 29779 0.94 [ 0.87, 0.98 ] 0.89 [ 0.89, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 72. ADAM 12 2T TO 1T RATIO.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 72 ADAM 12 2T TO 1T RATIO
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Baviera 2010 9 28 8 534 0.53 [ 0.28, 0.77 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 73. Stepwise: Age, 1T NT, 1T PAPP-A , 1T free ßhCG, if risk <1/30, 2T total hCG, 2T uE3, 2T AFP and
2T Inhibin A risk 1:270.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 73 Stepwise: Age, 1T NT, 1T PAPP-A , 1T free hCG, if risk <1/30, 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A risk 1:270
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cuckle 2008 79 1632 7 30637 0.92 [ 0.84, 0.97 ] 0.95 [ 0.95, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 74. Stepwise: Age, 1T NT, 1T PAPP-A , 1T free ßhCG, if risk <1/30, 2T free ßhCG, 2T uE3, 2T AFP and
2T Inhibin A risk 1:270.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 74 Stepwise: Age, 1T NT, 1T PAPP-A , 1T free hCG, if risk <1/30, 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A risk 1:270
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Aagaard-Tillery 2009 57 560 2 7223 0.97 [ 0.88, 1.00 ] 0.93 [ 0.92, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 75. Stepwise: Age, 1T NT, 1T PAPP-A , 1T free ßhCG, if risk <1/30, 2T free ßhCG, 2T uE3, 2T AFP and
2T Inhibin A 5% FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 75 Stepwise: Age, 1T NT, 1T PAPP-A , 1T free hCG, if risk <1/30, 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Aagaard-Tillery 2009 57 389 2 7394 0.97 [ 0.88, 1.00 ] 0.95 [ 0.94, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 76. Stepwise: Age, 1T NT, 1T PAPP-A , if risk <1:100, 2T free ßhCG, 2T uE3, 2T AFP, risk 1:250.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 76 Stepwise: Age, 1T NT, 1T PAPP-A , if risk <1:100, 2T free hCG, 2T uE3, 2T AFP, risk 1:250
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Habayeb 2010 11 48 1 1447 0.92 [ 0.62, 1.00 ] 0.97 [ 0.96, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 77. Contingent: Age, 1T NT, 1T PAPP-A , 1T free ßhCG, if risk 1/30-1/1500, 2T total hCG, 2T uE3, 2T
AFP and 2T Inhibin A risk 1:270.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 77 Contingent: Age, 1T NT, 1T PAPP-A , 1T free hCG, if risk 1/30-1/1500, 2T total hCG, 2T uE3, 2T AFP and 2T Inhibin A risk 1:270
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cuckle 2008 78 1467 8 30802 0.91 [ 0.82, 0.96 ] 0.95 [ 0.95, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 78. Contingent: Age, 1T NT, 1T PAPP-A , 1T free ßhCG, if risk 1/30-1/1500, 2T free ßhCG, 2T uE3, 2T
AFP and 2T Inhibin A risk 1:270.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 78 Contingent: Age, 1T NT, 1T PAPP-A , 1T free hCG, if risk 1/30-1/1500, 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A risk 1:270
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Aagaard-Tillery 2009 56 514 3 7269 0.95 [ 0.86, 0.99 ] 0.93 [ 0.93, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 79. Contingent: Age, 1T NT, 1T PAPP-A , 1T free ßhCG, if risk 1/30-1/1500, 2T free ßhCG, 2T uE3, 2T
AFP and 2T Inhibin A 5%FPR.
Review: First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening
Test: 79 Contingent: Age, 1T NT, 1T PAPP-A , 1T free hCG, if risk 1/30-1/1500, 2T free hCG, 2T uE3, 2T AFP and 2T Inhibin A 5%FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Aagaard-Tillery 2009 56 389 3 7394 0.95 [ 0.86, 0.99 ] 0.95 [ 0.94, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Direct comparisons of the diagnostic accuracy of the six most evaluated test strategies
Ratio of DORs
(95% CI); P value
(Studies)
1T PAPP-A, 2T to-
tal hCG, 2T uE3
and 2T AFP
1T PAPP-A, 2T to-
tal hCG, 2T uE3,
2T AFP and 2T In-
hibin A
1T NT, 2T total
hCG and 2T AFP
1T NT, 2T total
hCG, 2T uE3 and
2T AFP
1T NT, 1T PAPP-
A, 2T free ßhCG,
2T uE3, 2T AFP
and 2T Inhibin A
1T PAPP-A, 2T to-
tal hCG, 2T uE3,
2T AFP and 2T In-
hibin A
1.43 (0.39, 5.25); P
= 0.49
(K = 1)
1T NT, 2T total
hCG and 2T AFP
0.86 (0.25, 2.96); P
= 0.75
(K = 1)
0.60 (0.16, 2.22); P
= 0.34
(K = 1)
1T NT, 2T total
hCG, 2T uE3 and
2T AFP
1.23 (0.33, 4.57); P
= 0.68
(K = 1)
0.86 (0.22, 3.43); P
= 0.78
(K = 1)
1.44 (0.38, 5.41);
P = 0.49
(K = 1)
1T NT, 1T PAPP-
A, 2T free ßhCG,
2T uE3, 2T AFP
and 2T Inhibin A
2.97 (0.53, 16.6); P
= 0.15
(K = 1)
2.08 (0.35, 12.3); P
= 0.32
(K = 1)
3.48 (0.62,19.6);
P = 0.12
(K = 1)
2.41 (41, 14.3);
P = 0.24
(K = 1)
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Table 1. Direct comparisons of the diagnostic accuracy of the six most evaluated test strategies (Continued)
1T NT, 1T PAPP-
A, 2T total hCG,
2T uE3, 2T AFP
and 2T Inhibin A
2.41 (0.53, 11.0); P
= 0.18
(K = 1)
1.69 (0.35, 8.16); P
= 0.41
(K = 2)
2.82 (0.61, 13.0);
P = 0.13
(K = 1)
1.96 (0.40, 9.53);
P = 0.30
(K = 1)
1.87 (0.57, 6.06);
P = 0.26
(K = 2)
Direct comparisons were made using only data from studies that compared each pair of tests in the same population. Ratio of diagnostic
odds ratios (DORs) were computed by division of the DOR for the test in the row by the DOR for the test in the column. If the
ratio of DORs is greater than one, then the diagnostic accuracy of the test in the row is higher than that of the test in the column;
if the ratio is less than one, the diagnostic accuracy of the test in the column is higher than that of the test in the row. All test
combinations include maternal age. All test comparisons that were evaluated by only one study were from Wald 2003b.
1T = first trimester; 2T = second trimester; K = number of studies; CI = confidence interval
AFP = alpha-fetoprotein; ßhCG = beta human chorionic gonadotrophin; FPR = false positive rate; hCG = human chorionic go-
nadotrophin; NT = nuchal translucency; PAPP-A = pregnancy-associated plasma protein-A; uE3 = unconjugated oestriol.
Table 2. Indirect comparisons of the diagnostic accuracy of the six most evaluated test strategies
Ratio of DORs
(95% CI); P
value
1T PAPP-A, 2T
total hCG,
2T uE3 and 2T
AFP
1T PAPP-A, 2T
total hCG, 2T
uE3, 2T AFP
and 2T Inhibin
A
1T NT, 2T to-
tal hCG and 2T
AFP
1T NT, 2T total
hCG, 2T uE3
and 2T AFP
1T NT,
1T PAPP-A, 2T
free ßhCG, 2T
uE3, 2T AFP
and 2T Inhibin
A
DOR (95% CI)
Studies
96 (48, 190)
K =4
114 (62, 210)
K = 3
103 (49, 215)
K = 4
109 (51, 233)
K = 4
214 (125, 367)
K = 4
1T PAPP-A, 2T
total hCG, 2T
uE3, 2T AFP
and 2T Inhibin
A
114 (62, 210)
K = 3
1.19 (0.61, 2.32)
; P = 0.58
1T NT, 2T to-
tal hCG and 2T
AFP
103 (49, 215)
K = 4
1.08 (0.51, 2.36)
; P = 0.83
0.91 (0.43, 1.90)
; P = 0.78
1T NT, 2T total
hCG, 2T uE3
and 2T AFP
109 (51, 233)
K = 4
1.14 (0.54, 2.42)
; P = 0.71
0.96 (0.45, 2.03)
; P = 0.90
1.06 (0.47, 2.41)
;
P = 0.88
1T NT,
1T PAPP-A, 2T
free ßhCG, 2T
uE3, 2T AFP
and 2T Inhibin
A
214 (125, 367)
K = 4
2.24 (1.00, 5.00)
; P = 0.049
1.88 (0.88, 3.99)
; P = 0.094
2.08 (0.89, 4.87)
;
P = 0.09
1.96 (0.82, 4.67)
;
P = 0.12
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Table 2. Indirect comparisons of the diagnostic accuracy of the six most evaluated test strategies (Continued)
1T NT,
1T PAPP-A, 2T
total hCG, 2T
uE3, 2T AFP
and 2T Inhibin
A
339 (163, 705)
K = 3
3.55 (1.28, 9.89)
; P = 0.019
2.98 (1.14; 7.80)
; P = 0.029
3.29 (1.15, 9.47)
;
P = 0.030
3.11 (1.07, 9.07)
;
P = 0.039
1.58 (0.64, 3.95)
; P = 0.30
Indirect comparisons were made using all available data. Ratio of diagnostic odds ratios (DORs) were computed by division of the
DOR for the test in the row by the DOR for the test in the column. If the ratio of DORs is greater than one, then the diagnostic
accuracy of the test in the row is higher than that of the test in the column; if the ratio is less than one, the diagnostic accuracy of
the test in the column is higher than that of the test in the row. All test combinations include maternal age.
1T = first trimester; 2T = second trimester; K = number of studies; CI - confidence interval.
AFP = alpha-fetoprotein; ßhCG = beta human chorionic gonadotrophin; FPR = false positive rate; hCG = human chorionic go-
nadotrophin; NT = nuchal translucency; PAPP-A = pregnancy-associated plasma protein-A; uE3 = unconjugated oestriol.
Table 3. Comparison of integrated, contingent and stepwise strategy for a septuple combination of serum tests and first
trimester nuchal translucency
Test
combination
Screening pol-
icy
Study Women (cases) Sensitivity (95%
CI)
Specificity (95%
CI)
Threshold
First trimester
NT, PAPP-A and
free ßhCG, and
second trimester
uE3, AFP, to-
tal hCG and in-
hibin A
Integrated Malone 2005 33,546 (87) 94 (87, 98) 89 (89, 89) 1:150 risk
First trimester
NT, PAPP-A and
free ßhCG, if
risk <1:30 inva-
sive testing is of-
fered, if risk 1:
30-1:1500, sec-
ond trimester to-
tal hCG, uE3,
AFP and inhibin
A is performed
Contingent Cuckle 2008 32,355 (86) 91 (82, 96) 95 (95, 96) 1:270 risk
First trimester
NT, PAPP-A and
free ßhCG, if
risk <1:30 inva-
sive testing is of-
fered, if ≥ 1:30
second trimester
Stepwise Cuckle 2008 32,355 (86) 92 (84, 97) 95 (95, 95) 1:270 risk
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Table 3. Comparison of integrated, contingent and stepwise strategy for a septuple combination of serum tests and first
trimester nuchal translucency (Continued)
total hCG, uE3,
AFP and inhibin
A is performed
AFP = alpha-fetoprotein; ßhCG = beta human chorionic gonadotrophin; FPR = false positive rate; hCG = human chorionic go-
nadotrophin; NT = nuchal translucency; PAPP-A = pregnancy-associated plasma protein-A; uE3 = unconjugated oestriol.
CI - confidence interval.
Table 4. Maternal age, reference standard and study design characteristics of included studies
Study Maternal age (years)* Reference standard† Withdrawals
explained?
Study design
Aagaard-Tillery 2009 30.6 (SD 6.1) Karyotyping or follow-
up to birth
Of 33,546 trial partici-
pants only 7842 women
with complete informa-
tion for all screening
tests and genetic sonog-
raphy were included in
the study
Prospective cohort
Audibert 2001 30.1, all < 38, 86% < 35,
14% ≥35
Prenatal karyotype con-
ducted (in 7.
6% of patients) depend-
ing on presence of risk
>1/125, high maternal
age, parental anxiety, his-
tory of chromosomal de-
fects or parental translo-
cation or abnormal sec-
ond trimester scan. Cy-
togenetic testing of new-
borns with suspected ab-
normali-
ties. Postmortum on ter-
minations of pregnancy
or miscarriages. Follow-
up to neonatal examina-
tion in newborns
35 women were lost to
follow-up (they had all
had normal NT results).
340 women who did not
want second trimester
serum screening with-
drew from that part of
the study.Women lost to
follow-up were excluded
in the final analysis. All
detected cases were ter-
minated
Prospective consecutive
series
Babbur 2005 Median 37 (range 19 to
46)
Invasive testing offered
to women with NT > 3
mmor risk > 1:250 as de-
fined by combined NT
and serum results CVS
from 11 weeks, amnio-
centesis from 15 weeks)
. Rapid in situ hybridisa-
463 patients having NT
didnot goon tohave sec-
ond trimester serum test-
ing. Women with mis-
carriages excluded
Prospective cohort
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Table 4. Maternal age, reference standard and study design characteristics of included studies (Continued)
tion test in patients with
risk > 1:30. No details
given of any follow-up to
birth
Baviera 2010 35.3 for Down’s cases,
30.4 for controls
Amniocentesis or fol-
low-up to birth
No details of
withdrawals given.
Case control
Benattar 1999 32 (16 to 46), 8.3% > 35 Amniocentesis due to
maternal age > 38 years
(6.1% or women). Kary-
otyping encouraged for
women with positive re-
sult on one or more in-
dex test.Nodetails of ref-
erence standard for index
test negative women
No details
of withdrawals given. 12
patients were lost to fol-
low-up due to miscar-
riages
Prospective cohort
Bestwick 2010 Median 39 for Down’s
cases, 34 for non-Down’s
cases
Karyotyping or follow-
up to birth
No details of
withdrawals given.
Retrospective cohort
Cuckle 2008 Not reported Karyotyping or follow-
up to birth
No details of
withdrawals given.
Prospective cohort
Goh 1996 33 Karyotyping or follow-
up to birth
No details of
withdrawals given.
Cohort
Guanciali-Franchi 2010 31.8 Karyotyping or follow-
up to birth
No details of
withdrawals given.
Prospective cohort
Habayeb 2010 Median 35.4 (range 18
to 49)
Karyotyping or follow-
up to birth
No details of
withdrawals given.
Cohort
Herman 2002 Not reported Karyotyping or follow-
up to birth
No details of
withdrawals given.
Case control
Lam 2002 30.5 (19% ≥35) (unaf-
fected pregnancies)
Women considered high
risk offered CVS (0.7%)
or amniocentesis (11.
8%). Follow-up to birth
Details given for patients
excluded and those with-
out follow-up data
Prospective cohort
Malone 2005 21.6% aged 35 and
above
Amniocentesis (offered
to women with positive
results from any screen-
ing test) or follow-up to
birth
Details given for patients
whodidnot undergodif-
ferent index tests. Un-
clear which patients did
not have follow-up data.
Appears that aborted/
miscarried foetuses did
Prospective cohort
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Table 4. Maternal age, reference standard and study design characteristics of included studies (Continued)
not have follow-up
Okun 2008 Integrated 32 Karyotyping or follow-
up to birth
2614
(8%) of women under-
going integrated screen-
ing did not return for the
second trimester part of
the test
Prospective cohort
Palomaki 2006 33.9 (SD4.4) forDown’s
cases, 35.9 (SD 3.6) for
controls
Karyotyping or follow-
up to birth
No details of
withdrawals given.
Case control
Rodrigues 2009 30.
6 for integrated screen-
ing, 30.9 for serum inte-
grated screening
Karyotyping or follow-
up to birth
No details of
withdrawals given.
Retrospective cohort
Rozenberg 2002 30.5 (18 to 37) Amniocentesis offered to
patients with NT > 3
mm or serum marker
risk was > 1:250. Follow-
up to birth
No
details of withdrawals
given. 3.4% of patients
were lost to follow-up
and were excluded from
the study. This included
113 women (1.2%) with
miscarriages
Prospective cohort
Schuchter 2001 28 (range 15 to 46), 10.
7% aged 35 and above
CVS (offered to patients
with first trimester NT
> 3.5 mm), amniocen-
tesis (offered to patients
with first trimesterNT2.
5 to 3.4, high risk on sec-
ond trimester serum test-
ing (> 1:250) and those
> 35 years) or follow-up
to birth
No details of with-
drawals given. Women
having miscarriages were
excluded from the study
Retrospective cohort
Wald 2003b Not reported Invasive testing (follow-
ing sec-
ond trimester screening)
or follow-up to birth
No details of
withdrawals given.
Case control
Wald 2009 Median 33 (range 15 to
51), 20% aged 37 and
above
Karyotyping or follow-
up to birth
No details of
withdrawals given.
Retrospective cohort
Wright 2010 FASTER
trial
Not reported Karyotyping or follow-
up to birth
No details of
withdrawals given.
Case control
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Table 4. Maternal age, reference standard and study design characteristics of included studies (Continued)
Wright 2010 North York Not reported Karyotyping or follow-
up to birth
No details of
withdrawals given.
Case control
CVS = chorionic villus sampling; NT = nuchal translucency; SD = standard deviation
*Mean maternal age presented unless otherwise indicated.
†In all studies the choice of reference standard was dependent on the results of the index test.
A P P E N D I C E S
Appendix 1. Search Strategy
Database: Ovid MEDLINE
--------------------------------------------------------------------------------
1 exp Prenatal Diagnosis/
2 nuchal translucency.mp.
3 exp Pregnancy-Associated Plasma Protein-A/
4 pregnancy associated plasma protein a.mp.
5 papp-a.mp.
6 exp Chorionic Gonadotropin, beta Subunit, Human/
7 (b-hcg or bhcg).mp.
8 human chorionic gonadotropin.mp.
9 exp alpha-Fetoproteins/
10 alphafetoprotein$.mp.
11 alpha-fetoprotein$.mp.
12 afp.mp.
13 (unconjugated estriol or unconjugated oestriol).mp.
14 ue3.mp.
15 exp INHIBINS/
16 inhibin a.mp.
17 ultrasound.mp.
18 amniocentesis/
19 chorion$ vill$ sampling.mp.
20 Chorionic Villi-Sampling/
21 nasal bone.mp.
22 tricuspid regurgitation.mp.
23 ductus venosus.mp
24 marker$.mp.
25 screen$.mp.
26 detect$.mp.
27 accura$.mp.
28 predict$.mp.
29 ROC.mp.
30 ROC curve/
31 AUC.mp.
161First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
32 Area under curve/
33 exp false negative reactions/ or exp false positive reactions/
34 (false positive$ or false negative$).mp.
35 likelihood ratio$.mp.
36 sensitiv$.mp.
37 specific$.mp.
38 diagnos$.ti,ab.
39 “reproducibility of results”.mp.
40 reference value$.mp.
41 reference standard$.mp.
42 exp Down Syndrome/
43 downs syndrome.mp.
44 down syndrome.mp.
45 trisomy 21.mp.
46 Aneuploidy/
47 aneuploidy.mp.
48 Mosaicism/
49 mosaicism.mp.
50 or/1-41
51 or/42-49
52 50 and 51
53 (antenatal$ or prenatal$ or trimester$ or pregnan$ or fetus or foetus or fetal or foetal).mp.
54 52 and 53
55 animal/ not (humans/ and animal/)
56 54 not 55
*******************************************************
EMBASE via Dialog Datastar
1. PRENATAL-DIAGNOSIS#.DE.
2. FETUS-ECHOGRAPHY#.DE.
3. PREGNANCY-ASSOCIATED-PLASMA-PROTEIN-A#.DE.
4. CHORIONIC-GONADOTROPIN-BETA-SUBUNIT#.DE.
5. HCG.AB.
6. PAPP.AB.
7. ALPHA-FETOPROTEIN#.DE.
8. AFP.AB.
9. ALPHA ADJ FETOPROTEIN$
10. ALPHAFETOPROTEIN$
11. BETA ADJ HUMAN ADJ CHORIONIC ADJ GONADOTROPIN
12. PREGNANCY ADJ ASSOCIATED ADJ PLASMA ADJ PROTEIN
13. (UNCONJUGATED ADJ ESTRIOL OR UNCONJUGATED ADJ OESTRIOL).TI.
14. (UNCONJUGATED ADJ ESTRIOL OR UNCONJUGATED ADJ OESTRIOL).AB.
15. UE3
16. INHIBIN-A#.DE.
17. INHIBIN ADJ A
18. ULTRASOUND
19. AMNIOCENTESIS
20. CHORION-VILLUS-SAMPLING.DE.
21. NASAL ADJ BONE
22. TRICUSPID ADJ REGURGITATION
23. DUCTUS ADJ VENOSUS
24. MARKER OR MARKERS
25. SCREEN OR SCREENING
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26. DETECT OR DETECTING OR DETECTION
27. FALSE ADJ POSITIVE$
28. FALSE ADJ NEGATIVE$
29. SENSITIVITY OR SENSITIVE OR SENSITIVITIES
30. SPECIFICITY OR SPECIFICITIES
31. (DIAGNOSE OR DIAGNOSIS OR DIAGNOSTIC OR DIAGNOSTICS OR DIAGNOSES
OR DIAGNOSED).TI.
32. (DIAGNOSE OR DIAGNOSIS OR DIAGNOSTIC OR DIAGNOSTICS OR DIAGNOSES
OR DIAGNOSED).AB.
33. ROC.AB.
34. AUC.AB.
35. AREA-UNDER-THE-CURVE.DE.
36. ROC-CURVE.DE.
37. ACCURA$
38. PREDICT$
39. REPRODUCIBILITY.DE.
40. REFERENCE ADJ VALUE$
41. REFERENCE-VALUE.DE.
42. REFERENCE ADJ STANDARD$
43. DOWN-SYNDROME#.DE.
44. DOWN ADJ SYNDROME OR DOWNS ADJ SYNDROME
45. TRISOMY ADJ ’21’
46. MOSAICISM
47. ANEUPLOIDY
48. ANTENATAL$ OR PRENATAL$ OR PREGNANCYOR PREGNANTOR TRIMESTER$ ORMATERNAL OR FETUS
OR FOETUS OR FOETAL OR FETAL
49. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR
19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36
OR 37 OR 38 OR 39 OR 40 OR 42
50. 43 OR 44 OR 45 OR 46 OR 47
51. 48 AND 49 AND 50
52. HUMAN=YES
53. 51 AND 52
ADJ = adjacent AB = abstract
TI = title $ = truncation symbol DE = descriptor (similar to MeSH)
*******************************************************
CINAHL via OVID
--------------------------------------------------------------------------------
1 exp Prenatal Diagnosis/
2 nuchal translucency.mp.
3 pregnancy associated plasma protein.mp.
4 papp$.ti,ab.
5 exp Gonadotropins, chorionic/
6 (b-hcg or bhcg).mp.
7 human chorionic gonadotropin.mp.
8 exp alpha-Fetoproteins/
9 alphafetoprotein$.mp.
10 alpha-fetoprotein$.mp.
11 afp.mp.
12 (unconjugated estriol or unconjugated oestriol).mp.
13 ue3.mp.
14 inhibin$.mp.
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15 ultrasound.mp.
16 amniocentesis/
17 chorion$ vill$ sampling.mp.
18 Chorionic Villi-Sampling/
19 nasal bone.mp.
20 tricuspid regurgitation.mp.
21 ductus venosus.mp.
22 marker$.mp.
23 screen$.mp.
24 detect$.mp.
25 accura$.mp.
26 predict$.mp.
27 ROC.mp.
28 ROC curve/
29 AUC.mp.
30 “area under curve”.mp.
31 exp false negative reactions/ or exp false positive reactions/
32 (false positive$ or false negative$).mp.
33 likelihood ratio$.mp.
34 sensitiv$.mp.
35 specific$.mp.
36 diagnos$.ti,ab.
37 “reproducibility of results”.mp.
38 reference value$.mp.
39 reference standard$.mp.
40 exp Down Syndrome/
41 downs syndrome.mp.
42 down syndrome.mp.
43 trisomy 21.mp.
44 aneuploidy.mp.
45 mosaicism.mp.
46 (antenatal$ or prenatal$ or trimester$ or pregnan$ or fetus or foetus or fetal or foetal).mp.
47 or/1-39
48 or/40-45
49 47 and 48 and 46
*******************************************************
Search terms and instructions for Biosis
The following search terms were entered separately in standard search box (select ‘Titles/subject/abstract’ from the drop-down box on
the right of the search box).
1. “reference standard*”
2. “reference value*”
3. “reproducibility of results”
4. diagnos*
5. sensitiv*
6. specific*
7. “likelihood ratio*”
8. “false negative*
9. “false positive”
10. “area under curve”
11. ROC
12. AUC
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13. predict*
14. detect*
15. marker*
16. screen*
17. accura*
18. “ductus venosus”
19. “nasal bone”
20. “tricuspid regurgitation”
21. “chorion* vill* sampling”
22. amniocentesis
23. ultrasound
24. inhibin*
25. “unconjugaed oestriol”
26. “unconjugated estriol”
27. afp
28. “alpha fetoprotein*”
29. alphafetoprotein*
30. “ bhcg”
31. “human chorionic gonadotrophin”
32. “papp a”
33. “pregnancy associated plasma protein”
34. “nuchal translucency”
35. foetal
36. fetal
37. foetus
38. foetal
39. prenatal*
40. antenatal*
41. pregnan*
42. maternal*
43. “trisomy 21”
44. mosaicism
45. “down* syndrome”
The search then used the history function to combine terms:
1-34 - combine using OR
35 - 42 - combine using OR
43 - 45 - combine using OR
The three sets were combined using AND
The combined search strategy had the form
(((((((al: “trisomy 21”) or (al: (mosaicism))) or (al: “down* syndrome”))) and (((((((((((((((((((((((((((((((((((al: “reference stan-
dard*”) or (al: “reference value*”)) or (al: “reproducibility of results”)) or (al: (diagnos*))) or (al: (specific*))) or (al: (sensitiv*)))
or (al: “likelihood ratio*”)) or (al: “false negative*”)) or (al: “false positive*”)) or (al: “area under curve”)) or (al: (auc))) or (al:
(roc))) or (al: (predict*))) or (al: (accura*))) or (al: (detect*))) or (al: (screen*))) or (al: (marker*))) or (al: “ductus venosus”))
or (al: “tricuspid regurgitation”)) or (al: “nasal bone”)) or (al: “chorion* vill* sampling”)) or (al: (amniocentesis))) or (al:
(ultrasound))) or (al: (inhibin*))) or (al: “unconjugated oestriol”)) or (al: “unconjugated estriol”)) or (al: (afp))) or (al: “alpha
feto protein*”)) or (al: “alpha fetoprotein*”)) or (al: “b hcg”)) or (al: “human chorionic gonadotropin”)) or (al: “papp a”))
or (al: “pregnancy associated plasma protein”)) or (al: “nuchal translucency”)))) and (((((((((al: (foetal)) or (al: (fetal))) or (al:
(foetus))) or (al: (fetus))) or (al: (pregnan*))) or (al: (trimester*))) or (al: (prenatal*))) or (al: (antenatal*))))))
*******************************************************
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The Database of Abstracts of Reviews of Effectiveness (DARE), National Research Register and Health Services Research Projects in
Progress database
:
1. Down syndrome (MeSH)
2. down* next syndrome
3. trisomy
4. aneuploidy
5. mosaicism
6. OR/ 1-5
*******************************************************
MEDION (http://www.mediondatabase.nl/)
ICPC code for pregnancy - ‘W’.
*******************************************************
The Database of Systematic Reviews and Meta-Analyses in Laboratory Medicine - download the database to a .pdf file and search for
the following terms separately:
Down
Trisomy
Aneuploidy
Pregnant
Pregnancy
Pregnancies
Mosaicism
*******************************************************
Appendix 2. Glossary of terms (adapted in part from the UK National Screening Committee
Glossary)
Abnormal ductus venosus flow velocity The ductus venosus is a vessel in the fetus which allows oxygenated blood from the placenta
to bypass the fetal liver andflow straight to the heart. In conditions such asDown’s syndrome
the pressure in this vessel can be abnormally high
Absent nasal bone Absence of the bone that forms the bridge of the nose, which may be detected at ultrasound
scan during early pregnancy
Affected individuals Those individuals who are affected by the disorder for which they are being screened
Amniocentesis Amniocentesis is an invasive procedure which involves taking a small sample of the amniotic
fluid (liquor) surrounding the baby, using a needle which goes through the abdominal wall
into the uterus, and is usually performed after 15 weeks’ gestation
Chorionic villus sampling (CVS) Chorionic villus sampling involves taking a sample of the placental tissue using a needle
which goes through the abdominal wall and uterus or a cannula through the cervix. It is
usually performed between 10 and 13 weeks’ gestation
Combined test First trimester test (up to 13 + 6 weeks of pregnancy) based on combining nuchal translu-
cency measurement with free beta-hCG, pregnancy-associated plasma protein A (PAPP-A)
and the woman’s age
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Diagnostic accuracy The amount of agreement between the information from the index test and the reference
standard (see below)
Diagnostic test A definitive test, performed after a positive screening test result that gives a diagnosis (i.e.
yes or no)
Double test Second trimester test (from 13 + 6 up to 24 weeks of pregnancy) based on themeasurement
of alpha-fetoprotein (AFP), human chorionic gonadotrophin (hCG ß either free beta-hCG
or total hCG), together with the woman’s age
First trimester Pregnancy from conception up to 13 weeks and 6 days.
Iatrogenic A disease or condition in a patient occurring as a result of treatment
Index test A test or group of tests being evaluated in a systematic review
Integrated test Measurements performed at different times of pregnancy combined into a single test result.
Unless otherwise specified, ’integrated test’ refers to the combination of nuchal translucency
measurement and PAPP-A in the first trimester, with the quadruple test (see below) in the
second
Mosaicism This is a condition in which person has some cells containing a normal number of chro-
mosomes, and some containing an abnormal number. The more abnormal cells there are,
the greater the effect
Multiple of the median (MOM) The serum test concentration for a pregnant woman divided by the average (median) for
unaffected pregnancies in a defined population at the same stage of pregnancy
Quadruple test Second trimester test (from 13 + 6 up to 24 weeks of pregnancy) based on themeasurement
of AFP, uE3, free beta-hCG (or total hCG), and inhibin-A together with the woman’s age
Reference Standard The best available method for establishing the presence or absence of the target disease or
condition
Second trimester Pregnancy from14weeks to 28weeks’ gestation.Note that for the purposes of this Cochrane
review, second trimester testing refers to the period of 14 to 24 weeks’ gestation
Tricuspid regurgitation Leakiness of or backflow of blood through the tricuspid valve of the heart. The tricuspid
valve separates the upper and lower chambers of the right side of the heart
Triple test Second trimester test (from 14 up to 24 weeks of pregnancy) based on the measurement of
AFP, unconjugated oestriol (uE3), and hCG (either total hCG or free beta-hCG) together
with the woman’s age
Trisomy The presence of an extra chromosome resulting in three copies of a particular chromosome
instead of the normal two
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Translocation Part of one chromosome is broken off and attached to another chromosome. This does not
usually cause the individual any problems as they have a normal amount of chromosomes,
but in an abnormal arrangement. It can be passed on as an extra chromosome to offspring,
resulting in conditions such as Down’s syndrome
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The protocol intended to investigate several additional outcomes downstream from test accuracy, should they be reported in the test
accuracy studies. When we attempted to extract this information however, it was found to be available in very few studies, and where
such information was found it was difficult to extract meaningful data to allow for comparison between studies, as data were not
reported in a universal manner. In several studies such outcomes were estimated rather than measured. Often they were not reported
at all. The outcomes stated in the protocol which have not been included are: harms of testing; need for further testing; side effects
of test; interventions and side effects; other abnormalities detected by testing; spontaneous miscarriage; miscarriage subsequent to
invasive procedure, with or without normal karyotype; fetal karyotype; termination of pregnancy (prior to definitive testing or in
a karyotypically normal pregnancy and following confirmation of Down’s syndrome or following detection of other chromosomal
abnormalities); stillbirth; livebirth of affected and unaffected fetus; uptake of definitive testing by women.
The following refinements to the eligibility criteria were imposed to ensure that the quality of the included literature remained high.
We excluded studies that identified fewer than five Down’s syndrome pregnancies in their study population. We excluded studies that
had less than 80% follow-up of participants.
In addition, the analytical strategy was informed by the volume of tests and studies included, and developed so that we focused on key
tests and test combinations by a) only meta-analysed tests that were included in four or more studies or b) showed more than 70%
sensitivity for more than 95% specificity. In addition, a requirement that a minimum of 10 studies for a single test was required before
subgroup analysis was undertaken. Consequently several possible sources of heterogeneity were not investigated due to lack of data.
N O T E S
This review belongs to a suite of reviews examining antenatal screening for Down’s syndrome which includes:
• First trimester serum tests for Down’s syndrome screening (Alldred 2015);
• Urine tests for Down’s syndrome screening (Alldred 2015a)
• Second trimester serum tests for Down’s syndrome screening (Alldred 2012);
• First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening (in press)
• First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening (this
review).
The plans for these reviews were described in a generic protocol (Alldred 2010) published in the Cochrane Library in 2010. The
project as a whole has been much larger than initially anticipated, both in terms of size and statistical complexity. The initial search was
169First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
completed in 2007 and an updated search in August 2011. After identifying studies appropriate for inclusion, a significant amount of
time has been devoted to data management and analysis.
The authors are conscious of the time lag from the latest literature search to publication, and the potential for the introduction of new
urine tests in this time frame. The authors are also conscious of the potential for publication of new data pertaining to tests included in
this review. Whilst not fulfilling the usual Cochrane up-to-date criteria, this review is published because it provides historical context
in what is a rapidly-changing field, and because it is unlikely to ever be repeated.
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